TREATMENT READING
Breast Cancer
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
248 sections
- Hormone replacement therapy
- Surgical Treatment for Breast Cancer
- Surgical Staging of the Primary Tumor
- Axillary Lymph Node Management
- Breast Reconstruction
- Radiation Therapy for Breast Cancer
- Post–Breast-Conserving Surgery
- Omission of radiation therapy for favorable, early-stage breast cancer
- Partial breast irradiation
- Regional nodal irradiation
- Postmastectomy
- Timing of Postoperative Radiation Therapy
- Acute and Late Toxicities of Radiation Therapy
- Systemic Therapy for Stages I, II, and III Breast Cancer
- Patient Selection, Staging, Treatment, and Follow-Up
- Stages I, II, and III HER2-Negative Hormone Receptor–Positive Breast Cancer
- Preoperative endocrine therapy for HER2-negative hormone receptor–positive breast cancer
- Postoperative systemic therapy for HER2-negative hormone receptor–positive breast cancer
- Anthracycline-containing chemotherapy
- Non–anthracycline-containing regimens
- Timing of postoperative chemotherapy
- Endocrine therapy
- Tamoxifen
- Tamoxifen and chemotherapy
- Ovarian ablation, tamoxifen, and chemotherapy
- Aromatase inhibitors
- Premenopausal women
- Postmenopausal women
- Initial therapy
- Sequential tamoxifen and AI versus 5 years of tamoxifen
- Sequential tamoxifen and AI for 5 years versus an AI for 5 years
- One AI versus another for 5 years
- Switching to an AI after 5 years of tamoxifen
- Duration of AI therapy
- Endocrine therapy and cyclin-dependent kinase (CDK) inhibitor therapy
- Bone-Modifying Therapy for Stages I, II, and III Breast Cancer
- Adjuvant PARP Inhibitors for Patients with Germline BRCA1 and BRCA2 Variants
- Stages I, II, and III Triple-Negative Breast Cancer (TNBC)
- Preoperative therapy for TNBC
- Chemotherapy
- Immunotherapy
- Postoperative therapy for TNBC
- Capecitabine therapy
- Immunotherapy
- Stages I, II, and III HER2-Positive Breast Cancer
- Preoperative therapy for HER2-positive breast cancer
- Trastuzumab
- Pertuzumab
- Postoperative therapy for HER2-positive breast cancer
- Trastuzumab
- Pertuzumab
- Trastuzumab emtansine (T-DM1)
- Neratinib
- Node-negative, small, HER2-positive breast cancer
- Toxicity of Systemic Therapy
- Capecitabine and Fluorouracil Dosing
- Toxicity of Adjuvant Chemotherapy
- Cardiac Toxic Effects With Adjuvant Trastuzumab
- Cardiac Toxic Effects With Pertuzumab and Lapatinib
- Toxicity of Endocrine Therapy
- Treatment of Locoregional Recurrent Breast Cancer
- Treatment of Metastatic Breast Cancer
- Treatment Option Overview for Metastatic Breast Cancer
- Metastatic HER2-Negative Hormone Receptor–Positive Breast Cancer
- Endocrine therapy and cyclin-dependent kinase (CDK) inhibitor therapy
- First-line palbociclib and endocrine therapy
- First-line ribociclib and endocrine therapy
- First-line abemaciclib and endocrine therapy
- Second-line palbociclib and endocrine therapy
- Second-line ribociclib and endocrine therapy
- Second-line abemaciclib and endocrine therapy
- CDK inhibitor therapy after disease progression on a prior CDK inhibitor
- Single-agent CDK inhibitor therapy
- Mammalian target of rapamycin (mTOR) inhibitor therapy plus endocrine therapy
- AKT inhibitor therapy
- Capivasertib
- Alpelisib plus endocrine therapy
- Elacestrant
- HDAC inhibitor therapy
- Endocrine therapy alone
- Tamoxifen and AI therapy
- Fulvestrant
- First-line fulvestrant
- Second-line fulvestrant
- Combination endocrine therapy with an AI and fulvestrant
- Sequencing therapy for hormone receptor–positive metastatic breast cancer
- Poly (ADP-ribose) polymerase (PARP) inhibitor therapy
- Sacituzumab govitecan
- Chemotherapy
- Metastatic HER2-Low Breast Cancer
- Metastatic Triple-Negative Breast Cancer
- Chemotherapy plus immunotherapy
- Pembrolizumab
- Atezolizumab
- Sacituzumab govitecan
- PARP inhibitor therapy
- Chemotherapy
- Immunotherapy monotherapy
- Metastatic HER2-Positive Breast Cancer
- Monoclonal antibody therapy
- Trastuzumab
- Pertuzumab
- Trastuzumab emtansine
- Trastuzumab deruxtecan
- Margetuximab
- Tyrosine kinase inhibitor (TKI) therapy
- Tucatinib
- Neratinib
- Lapatinib
- mTOR inhibition
- Germline BRCA-Mutated Metastatic Breast Cancer
- Olaparib
- Talazoparib
- High Tumor Mutational Burden Breast Cancer
- Pembrolizumab
- Chemotherapy for Metastatic Breast Cancer
- Capecitabine and fluorouracil dosing
- Cardiac toxic effects with anthracyclines
- Surgical Treatment for Metastatic Breast Cancer
- Radiation Therapy for Metastatic Breast Cancer
- Bone-Modifying Therapy for Metastatic Breast Cancer
- Treatment of Ductal Carcinoma In Situ
- Introduction
- Treatment Options for DCIS
- Breast Cancer Treatment
- Join a Clinical Trial
- Local treatments
- Surgery for Breast Cancer
- Radiation for Breast Cancer
- Systemic treatments
- Chemotherapy for Breast Cancer
- Hormone Therapy for Breast Cancer
- Immunotherapy for Breast Cancer
- Targeted Therapy for Breast Cancer
- What kind of treatment will I receive?
- Breast Cancer Treatment by Stage
- Breast Cancer During Pregnancy
- Ductal Carcinoma in Situ (DCIS)
- Inflammatory Breast Cancer Treatment
- Triple-Negative Breast Cancer Treatment
- Paget Disease of the Breast
- Breast Cancer Treatment by Stage
- Treatment of stage 0 breast cancer (ductal carcinoma in situ)
- Treatment of stages I to III breast cancer
- Treatment of locoregional recurrent breast cancer
- Treatment of stage IV (metastatic) breast cancer
- Chemotherapy for Breast Cancer
- Who gets chemotherapy for breast cancer?
- When is chemotherapy for breast cancer given?
- Chemotherapy after surgery for breast cancer
- Chemotherapy before surgery for breast cancer
- Chemotherapy drugs used for breast cancer
- Side effects of chemotherapy
- Hormone Therapy for Breast Cancer
- Who gets hormone therapy?
- What types of hormone therapy are used for breast cancer?
- Therapies that block ovarian function (ovarian ablation)
- Aromatase inhibitors to block estrogen production
- Therapies that block estrogen’s effects
- How is hormone therapy used to treat breast cancer?
- Adjuvant therapy for early-stage breast cancer
- Neoadjuvant therapy for breast cancer
- Treatment of advanced, metastatic, or recurrent breast cancer
- What are the side effects of hormone therapy?
- What if side effects of hormone therapy interfere with my life?
- How effective is hormone therapy?
- Can other drugs interfere with hormone therapy?
- Immunotherapy for Breast Cancer
- Who gets immunotherapy for breast cancer?
- When is immunotherapy for breast cancer given?
- Immunotherapy drugs used for breast cancer
- Side effects of immunotherapy
- Inflammatory Breast Cancer Treatment
- Treating stage III (also called stage 3) inflammatory breast cancer
- Treating metastatic or stage IV (also called stage 4) inflammatory breast cancer
- Treatment for recurrent inflammatory breast cancer
- Clinical trials
- Coping with inflammatory breast cancer treatment
- Radiation for Breast Cancer
- Types of radiation therapy for breast cancer
- External beam radiation therapy for breast cancer
- Whole breast radiation therapy
- Partial breast external beam radiation therapy
- Intraoperative radiation therapy
- Brachytherapy for breast cancer
- Intracavitary brachytherapy
- Interstitial brachytherapy
- Permanent breast seed implant (PBSI)
- Intravenous radiation
- Side effects of radiation therapy for breast cancer
- Breast Cancer Surgery
- Learn More
- Breast Reconstruction After Mastectomy
- What is breast reconstruction?
- How do surgeons use implants to reconstruct a woman's breast?
- How do surgeons use tissue from a woman's own body to reconstruct the breast?
- How do surgeons reconstruct the nipple and areola?
- What factors can affect the timing of breast reconstruction?
- What factors can affect the choice of breast reconstruction method?
- Will health insurance pay for breast reconstruction?
- What type of follow-up care and rehabilitation is needed after breast reconstruction?
- Does breast reconstruction affect the ability to check for breast cancer?
- What is flat closure?
- What are some new developments in breast reconstruction after mastectomy?
- Choosing Between a Lumpectomy and Mastectomy
- Are you facing a decision about lumpectomy vs. mastectomy?
- Compare lumpectomy and mastectomy
- Questions about the effectiveness of breast cancer surgery
- Which type of breast cancer surgery is best for my cancer?
- Will the type of breast cancer surgery I have affect how long I live?
- What are the chances that my breast cancer will return in the same area?
- Questions about recovering from breast cancer surgery
- Will I have pain?
- How long before I can return to normal activities?
- What other problems might I have from breast cancer surgery?
- Questions about treatment after breast surgery
- What other types of treatment might I need after breast cancer surgery?
- Will I need more surgery?
- Questions about body image and quality of life after breast cancer surgery
- What will my breast look like after breast cancer surgery?
- Will my breast have feeling after breast cancer surgery?
- Will the type of breast surgery I choose affect my quality of life?
- Think about what is important to you
- Lumpectomy (Breast-Conserving Surgery)
- Treatment before or after lumpectomy
- Recovering from lumpectomy
- Reconstruction after lumpectomy
- Lumpectomy risks
- Mastectomy
- Types of mastectomy
- Single vs. double mastectomy
- Mastectomy with breast reconstruction surgery
- Going flat after a mastectomy
- Recovering after a mastectomy
- Mastectomy risks
- Targeted Therapy for Breast Cancer
- Who gets targeted therapy for breast cancer?
- When is targeted therapy for breast cancer given?
- Targeted therapy for HER2-positive breast cancer
- Targeted therapy for hormone receptor–positive breast cancer
- Targeted therapy for triple-negative breast cancer
- Targeted therapy for BRCA-positive breast cancer
- Side effects of targeted therapy
- Triple-Negative Breast Cancer Treatment
- Treating stages I–III triple-negative breast cancer
- Treating metastatic or stage IV (also called stage 4) triple-negative breast cancer
- Treatment for recurrent triple-negative breast cancer
- Clinical trials
Hormone replacement therapy
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
After careful consideration, certain patients with severe symptoms may be treated with hormone replacement therapy. For more information, see the Hormone Replacement Therapy section in Hot Flashes and Night Sweats and Breast Cancer Prevention.
Sources: Hormone Replacement Therapy · Breast Cancer Prevention
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Surgical Treatment for Breast Cancer
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Operable breast cancer requires a multimodal approach to treatment. After the presence of a malignancy is confirmed by biopsy, the following surgical treatment options can be discussed with the patient before a therapeutic procedure is selected:
Breast-conserving surgery.
Modified radical mastectomy (removal of the entire breast with axillary dissection of levels I and II) with or without breast reconstruction.
To guide the selection of neoadjuvant or adjuvant therapy, many factors including stage, grade, and molecular status of the tumor (e.g., estrogen receptor [ER], progesterone receptor [PR], human epidermal growth factor type 2 receptor [HER2], or triple-negative status) are considered.[1-5]
Surgical Staging of the Primary Tumor
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Selection of a local therapeutic approach depends on the following factors:[6]
Sources: 6
Location and size of the lesion.
Analysis of the mammogram and/or magnetic resonance imaging or additional imaging.
Breast size.
Patient’s desire to preserve the breast.
Options for surgical management of the primary tumor include:
Breast-conserving surgery (with consideration of radiation therapy). All histological types of invasive breast cancer may be treated with breast-conserving surgery plus radiation therapy.[7] However, the presence of inflammatory breast cancer, regardless of histological subtype, is a contraindication to breast-conserving therapy. The presence of multifocal disease in the breast and a history of collagen vascular disease are relative contraindications to breast-conserving therapy. Prior radiation to the breast was previously considered a contraindication to breast-conserving surgery. However, research has increasingly shown that repeat radiation therapy may be feasible and safe in select patient populations.[8]
Mastectomy with or without breast reconstruction.
Survival is equivalent with any of these options, as documented in the EORTC-10801 trial [9] and other prospective randomized trials.[10-16] Also, a retrospective study of 753 patients who were divided into three groups based on hormone receptor status (ER positive or PR positive; ER negative and PR negative but HER2 positive; and triple negative) found no differences in disease control within the breast in patients treated with standard breast-conserving surgery; however, there are not yet substantive data to support this finding.[17]
The rate of local recurrence in the breast after conservative treatment is low and varies slightly with the surgical technique used (e.g., lumpectomy, quadrantectomy, segmental mastectomy, and others). Whether completely clear microscopic margins are necessary has been debated.[18-20] However, a multidisciplinary consensus panel recently used margin width and ipsilateral breast tumor recurrence from a meta-analysis of 33 studies (N = 28,162 patients) as the primary evidence base for a new consensus regarding margins in patients with stage I and stage II breast cancer treated with breast-conserving surgery plus radiation therapy. Results of the meta-analysis include the following:[21]
Positive margins (ink on invasive carcinoma or ductal carcinoma in situ) were associated with a twofold increase in the risk of ipsilateral breast tumor recurrence compared with negative margins.
More widely clear margins were not found to significantly decrease the rate of ipsilateral breast tumor recurrence compared with no ink on tumor. Thus, it was recommended that the use of no ink on tumor be the new standard for an adequate margin in invasive cancer.
There was no evidence that more widely clear margins reduced ipsilateral breast tumor recurrence for young patients or for those with unfavorable biology, lobular cancers, or cancers with an extensive intraductal component.
For patients undergoing partial mastectomy, margins may be positive after primary surgery, often leading to re-excision. A clinical trial of 235 patients with stage 0 to III breast cancer who underwent partial mastectomy, with or without resection of selective margins, randomly assigned patients to have additional cavity shave margins resected (shave group) or not (no-shave group).[22] Patients in the shave group had a significantly lower rate of positive margins than those in the no-shave group (19% vs. 34%, P = .01) and a lower rate of second surgery for clearing margins (10% vs. 21%, P = .02).[22][Level of evidence B3]
Sources: 22 · 22 · Level of evidence B3
Axillary Lymph Node Management
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Axillary node status remains the most important predictor of outcome in patients with breast cancer. The axillary lymph nodes are staged to aid in determining prognosis and therapy.
Sentinel lymph node (SLN) biopsy is the initial standard axillary staging procedure performed in women with invasive breast cancer. The SLN is defined as any node that receives drainage directly from the primary tumor, allowing for more than one SLN, which is often the case. Studies have shown that the injection of technetium Tc 99m-labeled sulfur colloid, vital blue dye, or both around the tumor or biopsy cavity, or in the subareolar area, and subsequent drainage of these compounds to the axilla results in the identification of the SLN in 92% to 98% of patients.[23,24] These reports demonstrate a 97.5% to 100% concordance between SLN biopsy and complete axillary lymph node dissection (ALND). SLN biopsy alone is associated with less morbidity than axillary lymphadenectomy.[25-28]
Evidence (SLN biopsy):
ALMANAC, a randomized trial of 1,031 women compared SLN biopsy followed by ALND when the SLN was positive with ALND in all patients.[29][Level of evidence A3]
Sources: 29 · Level of evidence A3
ALMANAC, a randomized trial of 1,031 women compared SLN biopsy followed by ALND when the SLN was positive with ALND in all patients.[29][Level of evidence A3]
Quality of life at 1 year (as assessed by the frequency of patients experiencing a clinically significant deterioration in the Trial Outcome Index of the Functional Assessment of Cancer Therapy-Breast scale) was superior in the SLN biopsy group (23% deteriorating in the SLN biopsy group vs. 35% in the ALND group; P = .001). Arm function was also better in the SLN group.
The National Surgical Adjuvant Breast and Bowel Project’s (NSABP-B-32 [NCT00003830]) multicenter, phase III trial randomly assigned women (N = 5,611) to undergo either SLN plus ALND or SLN resection alone. ALND was only performed if the SLNs were positive.[30][Level of evidence A1]
Sources: NSABP-B-32 · 30 · Level of evidence A1
The National Surgical Adjuvant Breast and Bowel Project’s (NSABP-B-32 [NCT00003830]) multicenter, phase III trial randomly assigned women (N = 5,611) to undergo either SLN plus ALND or SLN resection alone. ALND was only performed if the SLNs were positive.[30][Level of evidence A1]
The study showed no detectable difference in overall survival (OS), disease-free survival (DFS), and regional control. The OS rate was 91.8% for SLN plus ALND versus 90.3% for SLN resection alone (P = .12).
Because of the following trial results, ALND is unnecessary after a positive SLN biopsy in patients with limited SLN-positive breast cancer treated with breast conservation or mastectomy, radiation therapy, and systemic therapy.
Evidence (ALND after a positive SLN biopsy in patients with limited SLN-positive breast cancer):
ACOSOG Z0011 (Alliance, NCT00003855), a phase III, noninferiority, multicenter, randomized clinical trial, evaluated whether ALND is required after a positive SLN biopsy. Women were randomly assigned to undergo ALND or no further axillary treatment. Patients had clinical T1 or T2 invasive breast cancer without palpable adenopathy and one to two SLNs containing metastases identified by frozen section. All patients underwent lumpectomy, tangential whole-breast radiation therapy, and appropriate systemic therapy. OS was the primary end point, and DFS was the secondary end point. Because of enrollment challenges, a total of 891 women out of a target enrollment of 1,900 women were randomly assigned to one of the two treatment arms.[Level of evidence A1]
Sources: ACOSOG Z0011 · Level of evidence A1
ACOSOG Z0011 (Alliance, NCT00003855), a phase III, noninferiority, multicenter, randomized clinical trial, evaluated whether ALND is required after a positive SLN biopsy. Women were randomly assigned to undergo ALND or no further axillary treatment. Patients had clinical T1 or T2 invasive breast cancer without palpable adenopathy and one to two SLNs containing metastases identified by frozen section. All patients underwent lumpectomy, tangential whole-breast radiation therapy, and appropriate systemic therapy. OS was the primary end point, and DFS was the secondary end point. Because of enrollment challenges, a total of 891 women out of a target enrollment of 1,900 women were randomly assigned to one of the two treatment arms.[Level of evidence A1]
At a median follow-up of 6.3 years, the 5-year OS rate was 91.8% (95% confidence interval [CI], 89.1%–94.5%) with ALND and 92.5% (95% CI, 90.0%–95.1%) with SLN biopsy alone.
Detailed analysis of the radiation field design found that 15% of patients also received treatment to the supraclavicular region (in addition to standard tangents). Of those with detailed radiation records available for review, 43 patients (18.9%) received regional nodal radiation therapy.[31]
Sources: 31
The 5-year DFS rate was 82.2% (95% CI, 78.3%–86.3%) with ALND and 83.9% (95% CI, 80.2%–87.9%) with SLN biopsy alone.
In a similarly designed trial (IBCSG 23-01), 929 women with breast tumors smaller than 5 cm and SLN involvement smaller than 2 mm were randomly assigned to ALND or no ALND.[32][Level of evidence A1]
Sources: 32 · Level of evidence A1
In a similarly designed trial (IBCSG 23-01), 929 women with breast tumors smaller than 5 cm and SLN involvement smaller than 2 mm were randomly assigned to ALND or no ALND.[32][Level of evidence A1]
Patients without axillary dissection had fewer DFS events (hazard ratio [HR], 0.78; 95% CI, 0.55–1.11).
No difference in OS was observed.
The AMAROS trial (NCT00014612) studied ALND and axillary radiation therapy after identification of a positive SLN.[33][Level of evidence A1]
Sources: AMAROS · 33 · Level of evidence A1
The AMAROS trial (NCT00014612) studied ALND and axillary radiation therapy after identification of a positive SLN.[33][Level of evidence A1]
ALND and axillary radiation therapy provided excellent and comparable axillary control for patients with T1 or T2 primary breast cancer and no palpable lymphadenopathy who underwent breast-conserving therapy or mastectomy.
The use of axillary radiation therapy was also associated with significantly less morbidity.
For patients who require an ALND, the standard evaluation usually involves only a level I and II dissection, thereby removing a satisfactory number of nodes for evaluation (i.e., at least 6–10), while reducing morbidity from the procedure.
Although SLN biopsy has been the standard for the axillary staging of patients with invasive breast cancer and a clinically negative axilla, two randomized controlled trials have identified populations for which SLN biopsy could be omitted.
Evidence (omission of SLN biopsy):
The SOUND trial (NCT02167490), a multicenter, noninferiority, randomized clinical trial, evaluated omitting SLN biopsy in women with invasive breast cancer. Patients were of any age, had tumors smaller than 2 cm, had negative preoperative axillary ultrasonography, and planned to receive breast-conserving surgery and adjuvant radiation therapy. A total of 1,493 women were randomly assigned to undergo SLN biopsy or no axillary surgery. The median follow-up was 5.7 years.[34][Level of evidence A1]
Sources: SOUND · 34 · Level of evidence A1
The SOUND trial (NCT02167490), a multicenter, noninferiority, randomized clinical trial, evaluated omitting SLN biopsy in women with invasive breast cancer. Patients were of any age, had tumors smaller than 2 cm, had negative preoperative axillary ultrasonography, and planned to receive breast-conserving surgery and adjuvant radiation therapy. A total of 1,493 women were randomly assigned to undergo SLN biopsy or no axillary surgery. The median follow-up was 5.7 years.[34][Level of evidence A1]
The 5-year distant DFS rate was 97.7% in the SLN biopsy group and 98.0% in the no-surgery group (log-rank P = .67; HR, 0.84; 90% CI, 0.45–1.54; noninferiority P = .02).
A total of 12 locoregional relapses (1.7%), 13 distant metastases (1.8%), and 21 deaths (3.0%) were observed in the SLN biopsy group, compared with 11 locoregional relapses (1.6%), 14 distant metastases (2.0%), and 18 deaths (2.6%) in the no-surgery group.
The multicenter, noninferiority, randomized INSEMA trial (NCT02466737) evaluated omitting SLN biopsy in 5,502 women with clinically node-negative invasive breast cancer. Tumors had to be smaller than 5 cm, and most patients had T1 disease and ER-positive tumors. Patients were scheduled to undergo breast-conserving surgery and whole-breast radiation therapy. Patients were randomly assigned in a 1:4 ratio to undergo no axillary surgery or SLN biopsy. The median follow-up was 6 years.[35][Level of evidence A1]
Sources: INSEMA · 35 · Level of evidence A1
The multicenter, noninferiority, randomized INSEMA trial (NCT02466737) evaluated omitting SLN biopsy in 5,502 women with clinically node-negative invasive breast cancer. Tumors had to be smaller than 5 cm, and most patients had T1 disease and ER-positive tumors. Patients were scheduled to undergo breast-conserving surgery and whole-breast radiation therapy. Patients were randomly assigned in a 1:4 ratio to undergo no axillary surgery or SLN biopsy. The median follow-up was 6 years.[35][Level of evidence A1]
The 5-year invasive DFS rate was 91.9% in the no-surgery group and 91.7% in the SLN biopsy group (HR, 0.91; 95% CI, 0.73–1.14), which was below the prespecified noninferiority margin.
Patients in the no-surgery group had a lower incidence of lymphedema, greater arm mobility, and less pain with movement of the arm or shoulder than patients who underwent SLN biopsy.
Breast Reconstruction
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
For patients who opt for a total mastectomy, reconstructive surgery may be performed at the time of the mastectomy (immediate reconstruction) or at some subsequent time (delayed reconstruction).[36-39] Breast contour can be restored by the following procedures:
Mastopexy.
Submuscular insertion of an artificial implant (silicone or saline filled). If an immediate implant cannot technically be performed, a tissue expander can be inserted beneath the pectoral muscle. Saline is injected into the expander to stretch the tissues for a period of weeks or months until the desired volume is obtained. The tissue expander is then replaced by a permanent implant. For more information on breast implants, see the U.S. Food and Drug Administration.
Sources: U.S. Food and Drug Administration
Rectus muscle or other flap. Muscle flaps require a considerably more complicated and prolonged operative procedure, and blood transfusions may be required.
After breast reconstruction, radiation therapy can be delivered to the chest wall and regional nodes if indicated in either the adjuvant or local recurrent disease setting. Radiation therapy after reconstruction with either a breast prosthesis or a tissue flap may affect cosmesis and symmetry. The incidence of capsular fibrosis, pain, or the need for implant removal may also be increased.[40]
Sources: 40
Radiation Therapy for Breast Cancer
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Radiation therapy is standard after breast-conserving surgery as part of breast-conserving therapy. Radiation therapy is also considered for high-risk postmastectomy patients. The main goal of adjuvant radiation therapy is to eradicate residual disease, reducing local recurrence and increasing breast cancer–specific survival.[1]
Sources: 1
Post–Breast-Conserving Surgery
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
For women who have breast-conserving surgery without radiation therapy, the risk of recurrence in the conserved breast is substantial (>20%) even in women with confirmed axillary lymph node–negative disease.[2] Although all trials assessing the role of radiation therapy in breast-conserving therapy have shown highly statistically significant reductions in local recurrence rate, no single trial has demonstrated a statistically significant reduction in mortality. However, a large meta-analysis demonstrated a significant reduction in risk of recurrence and breast cancer death.[3] Overall, evidence supports the use of whole-breast radiation therapy after breast-conserving surgery.
Evidence (breast-conserving surgery followed by radiation therapy):
A 2011 meta-analysis of 17 clinical trials performed by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), which included over 10,000 women with early-stage breast cancer, supported whole-breast radiation therapy after breast-conserving surgery.[3][Level of evidence A1]
Sources: 3 · Level of evidence A1
A 2011 meta-analysis of 17 clinical trials performed by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), which included over 10,000 women with early-stage breast cancer, supported whole-breast radiation therapy after breast-conserving surgery.[3][Level of evidence A1]
Whole-breast radiation therapy resulted in a significant reduction in the 10-year risk of recurrence compared with breast-conserving surgery alone (19% for whole-breast radiation therapy vs. 35% for breast-conserving surgery alone; relative risk [RR], 0.52; 95% confidence interval [CI], 0.48–0.56) and a significant reduction in the 15-year risk of breast cancer death (21% for whole-breast radiation therapy vs. 25% for breast-conserving surgery alone; RR, 0.82; 95% CI, 0.75–0.90).
Regarding radiation dosing and schedule, the following has been noted:
Whole-breast radiation dose. Conventional whole-breast radiation therapy is delivered to the whole breast (with or without regional lymph nodes) in 1.8 Gy to 2 Gy daily fractions over 5 to 6.5 weeks to a total dose of 45 Gy to 50 Gy.
Radiation boost. A further radiation boost is commonly given to the tumor bed. Two randomized trials conducted in Europe have shown that boosts of 10 Gy to 16 Gy reduce the risk of local recurrence from 4.6% to 3.6% at 3 years (P = .044),[4][Level of evidence B1] and from 7.3% to 4.3% at 5 years (P < .001).[5][Level of evidence B1] Results were similar after a median follow-up of 17.2 years.[6][Level of evidence B1] If a boost is used, it can be delivered either by external-beam radiation therapy, generally with electrons, or by using an interstitial radioactive implant.[7] Administering a radiation boost may, however, be associated with unfavorable quality-of-life outcomes.[8]
Sources: 4 · Level of evidence B1 · 5 · Level of evidence B1 · 6 · Level of evidence B1 · 7 · 8
Radiation schedule. Some studies show that a shorter fractionation schedule of 42.5 Gy over 3 to 4 weeks is a reasonable alternative for some patients with breast cancer.
Radiation schedule. Some studies show that a shorter fractionation schedule of 42.5 Gy over 3 to 4 weeks is a reasonable alternative for some patients with breast cancer.
A noninferiority trial of 1,234 randomly assigned patients with node-negative invasive breast cancer analyzed locoregional recurrence rates with conventional whole-breast radiation therapy versus a shorter fractionation schedule.[9] The 10-year locoregional relapse rate among women who received shorter fractionation was not inferior to conventional whole-breast radiation therapy (6.2% for a shorter fractionation schedule vs. 6.7% for whole-breast radiation therapy with absolute difference, 0.5 percentage points; 95% CI, −2.5 to 3.5).[9][Level of evidence B1
Sources: 9 · 9 · Level of evidence B1
Similarly, a combined analysis of the randomized United Kingdom Standardisation of Breast Radiotherapy trials (START), (START-A [ISRCTN59368779]) and START-B [ISRCTN59368779]) revealed no difference in a 10-year locoregional relapse rate. These trials collectively randomly assigned 4,451 women with completely excised invasive (pT1–3a, pN0–1, M0) early-stage breast cancer after breast-conserving surgery to receive conventional whole-breast radiation therapy dosing or shorter fractionation.[10][Level of evidence B1]
Sources: 10 · Level of evidence B1
A meta-analysis that included the three trials mentioned above plus six others confirmed that differences with respect to local recurrence or cosmesis between shorter and conventional fractionation schedules were neither statistically nor clinically significant.[11]
Sources: 11
Additional studies are needed to determine whether shorter fractionation is appropriate for women with higher nodal disease burden.[10]
Sources: 10
Omission of radiation therapy for favorable, early-stage breast cancer
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
The omission of radiation therapy after breast-conserving surgery has been tested in older patients with early-stage (T1 and small T2), hormone receptor–positive tumors after primary surgery. Two large trials found that radiation can be safely omitted without survival deficit, but with an increased risk of local recurrence of about 8% at 10 years, assuming that hormonal therapy is used.
CALGB 9343 was a phase III randomized trial of radiation omission. A total of 636 women were enrolled; 317 women received tamoxifen plus radiation therapy, and 319 women received tamoxifen alone. Eligible women were aged 70 years or older and had clinical stage I estrogen receptor (ER)-positive breast cancer. Initial eligibility criteria included breast cancers measuring up to 4 cm regardless of ER status, but in August 1996 this was reduced to measuring up to 2 cm (T1) with ER-positive or indeterminate receptor status. Patients were required to have clinically negative axillae.[12][Level of evidence A1]
Sources: 12 · Level of evidence A1
CALGB 9343 was a phase III randomized trial of radiation omission. A total of 636 women were enrolled; 317 women received tamoxifen plus radiation therapy, and 319 women received tamoxifen alone. Eligible women were aged 70 years or older and had clinical stage I estrogen receptor (ER)-positive breast cancer. Initial eligibility criteria included breast cancers measuring up to 4 cm regardless of ER status, but in August 1996 this was reduced to measuring up to 2 cm (T1) with ER-positive or indeterminate receptor status. Patients were required to have clinically negative axillae.[12][Level of evidence A1]
At 10 years, 98% of patients in the tamoxifen-plus-radiation group (95% CI, 96%–99%) were free from local and regional recurrences compared with 90% in the tamoxifen-alone group (95% CI, 85%–93%).
There were no significant differences in time-to-mastectomy, time-to-distant metastasis, breast cancer–specific survival, or survival between the two groups. The 10-year overall survival (OS) rate was 67% (95% CI, 62%–72%) in the tamoxifen-plus-radiation group, and 66% (95% CI, 61%–71%) in the tamoxifen-alone group.
PRIME-II was a phase III trial of radiation omission. A total of 1,326 women were randomly assigned to receive either whole-breast irradiation (n = 658) or no irradiation (n = 668). Eligible women were aged 65 years or older and had hormone receptor–positive, node-negative, T1 or T2 primary breast cancer (with tumors measuring ≤3 cm in the largest dimension). Patients had previously undergone breast-conserving surgery with clear excision margins and adjuvant endocrine therapy.[13][Level of evidence A1]
Sources: 13 · Level of evidence A1
PRIME-II was a phase III trial of radiation omission. A total of 1,326 women were randomly assigned to receive either whole-breast irradiation (n = 658) or no irradiation (n = 668). Eligible women were aged 65 years or older and had hormone receptor–positive, node-negative, T1 or T2 primary breast cancer (with tumors measuring ≤3 cm in the largest dimension). Patients had previously undergone breast-conserving surgery with clear excision margins and adjuvant endocrine therapy.[13][Level of evidence A1]
At a median follow-up of 10 years, the cumulative incidence of local breast cancer recurrence was 9.5% (95% CI, 6.8%–12.3%) in the no-radiation therapy group and 0.9% (95% CI, 0.1%–1.7%) in the radiation therapy group. The 10-year OS rate was almost identical in the two groups, at 80.8% (95% CI, 77.2%–84.3%) in the no-radiation therapy group and 80.7% (95% CI, 76.9%–84.3%) in the radiation therapy group.
Partial breast irradiation
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Guidelines that address identifying appropriate candidates for partial breast irradiation have been published.[14]
Sources: 14
Evidence (partial breast irradiation):
The RAPID trial (NCT00282035) randomly assigned 2,135 women aged 40 years or older with ductal carcinoma in situ or node-negative breast cancer treated by breast-conserving surgery to receive either external-beam accelerated partial breast irradiation (APBI) (38.5 Gy in ten fractions delivered twice per day over 5–8 days) or whole-breast radiation therapy (42.5 Gy in 16 fractions delivered once per day over 21 days, or 50 Gy in 25 fractions once per day over 35 days).[15] Sixty-five ipsilateral breast tumor recurrences were observed, 37 in the APBI group, and 28 in the whole-breast irradiation group.
The RAPID trial (NCT00282035) randomly assigned 2,135 women aged 40 years or older with ductal carcinoma in situ or node-negative breast cancer treated by breast-conserving surgery to receive either external-beam accelerated partial breast irradiation (APBI) (38.5 Gy in ten fractions delivered twice per day over 5–8 days) or whole-breast radiation therapy (42.5 Gy in 16 fractions delivered once per day over 21 days, or 50 Gy in 25 fractions once per day over 35 days).[15] Sixty-five ipsilateral breast tumor recurrences were observed, 37 in the APBI group, and 28 in the whole-breast irradiation group.
In patients treated with APBI, the 5-year cumulative rate of ipsilateral breast tumor recurrence was 2.3% (95% CI, 1.4%–3.2%) and the 8-year cumulative rate was 3.0% (95% CI, 1.9%–4.0%).
In patients treated with whole-breast radiation therapy, the 5-year cumulative rate of ipsilateral breast tumor recurrence was 1.7% (range, 0.9%–2.5%) and the 8-year cumulative rate was 2.8% (range, 1.8%–3.9%).
The hazard ratio (HR) for APBI versus whole-breast radiation therapy was 1.27 (90% CI, 0.84–1.91).
Thus, the upper bound of the estimated 90% CI did not exceed the noninferiority margin of 2.02. The APBI arm was associated with less short-term but more long-term toxicity.[15][Level of evidence B1]
Sources: 15 · Level of evidence B1
The NSABP B-39/RTOG 0413 trial (NCT00103181) randomly assigned 4,216 women to whole-breast radiation therapy or APBI.[16] Whole-breast radiation therapy was delivered in 25 daily fractions of 50 Gy over 5 weeks, with or without a supplemental boost to the tumor bed, and APBI was delivered as 34 Gy of brachytherapy or 38.5 Gy of external-bream radiation therapy in 10 fractions, over 5 treatment days within an 8-day period.
Sources: NSABP B-39/RTOG 0413 · 16
The NSABP B-39/RTOG 0413 trial (NCT00103181) randomly assigned 4,216 women to whole-breast radiation therapy or APBI.[16] Whole-breast radiation therapy was delivered in 25 daily fractions of 50 Gy over 5 weeks, with or without a supplemental boost to the tumor bed, and APBI was delivered as 34 Gy of brachytherapy or 38.5 Gy of external-bream radiation therapy in 10 fractions, over 5 treatment days within an 8-day period.
At a median follow-up of 10.2 years (interquartile range, 7.5–11.5), 90 of 2,089 women (4%) eligible for the primary outcome in the APBI group and 71 of 2,036 women (3%) in the whole-breast radiation therapy group had an ipsilateral breast tumor recurrence (HR, 1.22; 90% CI, 0.94–1.58). The results did not meet the prespecified criterion for equivalence, an HR of 1.50 or less.
Toxicity was not substantially different between the arms.[16][Level of evidence B1]
Sources: 16 · Level of evidence B1
The randomized, phase III, single-center APBI-IMRT-Florence trial (NCT02104895) evaluated differences in ipsilateral breast tumor recurrence (IBTR) among patients who received APBI using either intensity-modulated radiation therapy, an advanced radiation technique, (30 Gy in five once-daily fractions) or whole-breast radiation therapy with tangents (50 Gy in 25 fractions with a tumor bed boost). Patients had previously undergone breast-conserving surgery. A total of 520 patients were randomly assigned (whole-breast radiation therapy, n = 260; APBI, n = 260).[17]
Sources: APBI-IMRT-Florence · 17
The randomized, phase III, single-center APBI-IMRT-Florence trial (NCT02104895) evaluated differences in ipsilateral breast tumor recurrence (IBTR) among patients who received APBI using either intensity-modulated radiation therapy, an advanced radiation technique, (30 Gy in five once-daily fractions) or whole-breast radiation therapy with tangents (50 Gy in 25 fractions with a tumor bed boost). Patients had previously undergone breast-conserving surgery. A total of 520 patients were randomly assigned (whole-breast radiation therapy, n = 260; APBI, n = 260).[17]
The 10-year cumulative incidence of IBTR was 2.5% in the whole-breast radiation therapy arm and 3.7% in the APBI arm (HR, 1.56; 95% CI, 0.55–4.37; P = .40).
The 10-year OS rate was 91.9% in both arms (HR, 0.95; 95% CI, 0.50–1.79; P = .86). Breast cancer–specific survival at 10 years was 96.7% in the whole-breast radiation therapy arm and 97.8% in the APBI arm (HR, 0.65; 95% CI, 0.21–1.99; P = .45).
There were fewer acute and late toxicities in the APBI arm (P = .0001 for both comparisons). The APBI arm had improved cosmetic outcomes as evaluated by both physicians and patients (P = .0001 for both comparisons).
Regional nodal irradiation
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Regional nodal irradiation is routinely given postmastectomy to patients with involved lymph nodes; however, its role in patients who have breast-conserving surgery and whole-breast radiation therapy has been less clear. A randomized trial (NCT00005957) of 1,832 women showed that administering regional nodal irradiation after breast-conserving surgery and whole-breast radiation therapy reduced the risk of recurrence (10-year disease-free survival [DFS] rate, 82.0% vs. 77.0%; HR, 0.76; 95% CI, 0.61–0.94; P = .01) but did not affect survival (10-year OS rate, 82.8% vs. 81.8%; HR, 0.91; 95% CI, 0.72–1.13; P = .38).[18][Level of evidence A1]
Sources: NCT00005957 · 18 · Level of evidence A1
Similar findings were reported from the EORTC trial (NCT00002851). Women with a centrally or medially located primary tumor with or without axillary node involvement, or an externally located tumor with axillary involvement, were randomly assigned to receive whole-breast or thoracic-wall radiation therapy in addition to regional nodal irradiation or not. Breast-conserving surgery was performed for 76.1% of the study population, and the remaining participants underwent mastectomy. No improvement in OS was seen at 10 years among patients who underwent regional nodal irradiation, compared with patients who did not undergo regional nodal radiation (82.3% vs. 80.7%, P = .06). Distant DFS was improved among patients who underwent regional nodal irradiation when compared with patients who did not undergo regional nodal irradiation (78% vs. 75%, P = .02).[19][Level of evidence A1]
Sources: NCT00002851 · 19 · Level of evidence A1
A meta-analysis of individual patient data from all randomized trials of regional lymph node radiation therapy versus no regional lymph node radiation therapy in women with early breast cancer included 16 clinical trials involving 14,324 participants. It found that radiation therapy significantly reduced breast cancer mortality (RR, 0.87; 95% CI, 0.80–0.94; P = .0010), with no significant effect on non–breast cancer mortality (RR, 0.97; 0.84–1.11; P = .63), leading to significantly reduced all-cause mortality (RR, 0.90; 0.84–0.96; P = .0022). Estimated absolute reductions in 15-year breast cancer mortality were 1.6% for women with zero positive axillary nodes, 2.7% for those with one to three positive axillary nodes, and 4.5% for those with four or more positive axillary nodes.[20]
Sources: 20
Postmastectomy
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Postoperative chest wall and regional lymph node adjuvant radiation therapy has traditionally been given to selected patients considered at high risk of locoregional failure after mastectomy. Patients at highest risk of local recurrence meet one or more of the following criteria:[21-23]
Four or more positive axillary nodes.
Grossly evident extracapsular nodal extension.
Lymphovascular space invasion.
Large primary tumors.
Very close or positive deep margins of resection of the primary tumor.
In this high-risk group, radiation therapy can decrease locoregional recurrence, even among patients who receive adjuvant chemotherapy.[24]
Sources: 24
Patients with one to three involved nodes without any of the high-risk factors may be at a lower risk of local recurrence, and the value of routine use of adjuvant radiation therapy in this setting is an area of controversy.
Evidence (postoperative radiation therapy in patients with one to three involved lymph nodes):
The 2005 EBCTCG meta-analysis of 42,000 women in 78 randomized treatment comparisons indicated that radiation therapy is beneficial, regardless of the number of lymph nodes involved.[1][Level of evidence A1]
Sources: 1 · Level of evidence A1
The 2005 EBCTCG meta-analysis of 42,000 women in 78 randomized treatment comparisons indicated that radiation therapy is beneficial, regardless of the number of lymph nodes involved.[1][Level of evidence A1]
For women with node-positive disease postmastectomy and axillary clearance (removal of axillary lymph nodes and surrounding fat), radiation therapy reduced the 5-year local recurrence risk from 23% to 6% (absolute gain, 17%; 95% CI, 15.2%–18.8%). This translated into a significant reduction (P = .002) in breast cancer mortality, 54.7% versus 60.1%, with an absolute gain of 5.4% (95% CI, 2.9%–7.9%).
In subgroup analyses, the 5-year local recurrence rate was reduced by 12% (95% CI, 8%–16%) for women with one to three involved lymph nodes and by 14% (95% CI, 10%–18%) for women with four or more involved lymph nodes. In an updated meta-analysis of 1,314 women with axillary dissection and one to three positive nodes, radiation therapy reduced locoregional recurrence (2-sided P < .00001), overall recurrence (RR, 0.68; 95% CI, 0.57–0.82; 2-sided P = .00006), and breast cancer mortality (RR, 0.80; 95% CI, 0.67–0.95; 2-sided P = .01).[25][Level of evidence A1]
Sources: 25 · Level of evidence A1
In contrast, for women at low risk of local recurrence with node-negative disease, the absolute reduction in 5-year local recurrence was only 4% (P = .002; 95% CI, 1.8%–6.2%), and there was not a statistically significant reduction in 15-year breast cancer mortality (absolute gain, 1.0%; P > .1; 95% CI, -0.8%–2.8%).
Further, an analysis of National Surgical Adjuvant Breast and Bowel Project (NSABP) trials showed that even in patients with large (>5 cm) primary tumors and negative axillary lymph nodes, the risk of isolated locoregional recurrence was low enough (7.1%) that routine locoregional radiation therapy was not warranted.[26]
Sources: 26
Timing of Postoperative Radiation Therapy
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
The optimal sequence of adjuvant chemotherapy and radiation therapy after breast-conserving surgery has been studied. Based on studies, delaying radiation therapy for several months after breast-conserving surgery until the completion of adjuvant chemotherapy does not appear to have a negative impact on overall outcome. Additionally, initiating chemotherapy soon after breast-conserving surgery may be preferable for patients at high risk of distant dissemination.
Evidence (timing of postoperative radiation therapy):
In a randomized trial, patients received one of the following regimens:[27][Level of evidence A1]The following results were observed:
Sources: 27 · Level of evidence A1
In a randomized trial, patients received one of the following regimens:[27][Level of evidence A1]The following results were observed:
Chemotherapy first (n = 122), consisting of cyclophosphamide, methotrexate, fluorouracil (5-FU), and prednisone plus doxorubicin repeated every 21 days for four cycles, followed by breast radiation.
Breast radiation first (n = 122), followed by the same chemotherapy.
With a median follow-up of 5 years, OS was 73% for the radiation-first group and 81% for the chemotherapy-first group (P = .11).
The 5-year crude rate of first recurrence by site was 5% in the radiation-first group and 14% in the chemotherapy-first group for local recurrence and 32% in the radiation-first group and 20% in the chemotherapy-first group for distant or regional recurrence or both. This difference in the pattern of recurrence was of borderline statistical significance (P = .07).
Further analyses revealed that differences in recurrence patterns persisted for most subgroups except for those who had either negative tumor margins or one to three positive lymph nodes. For these two subgroups, sequence assignment made little difference in local or distant recurrence rates, although the statistical power of these subgroup analyses was low.
Potential explanations for the increase in distant recurrence noted in the radiation-first group are that chemotherapy was delayed for a median of 17 weeks after surgery, and that this group received lower chemotherapy dosages because of increased myelosuppression.
Two additional randomized trials, though not specifically designed to address the timing of radiation therapy and adjuvant chemotherapy, do add useful information.
Two additional randomized trials, though not specifically designed to address the timing of radiation therapy and adjuvant chemotherapy, do add useful information.
In the NSABP-B-15 trial, patients who had undergone breast-conserving surgery received either one course of cyclophosphamide, methotrexate, and 5-FU (CMF) (n = 194) followed by radiation therapy followed by five additional cycles of CMF, or they received four cycles of doxorubicin and cyclophosphamide (n = 199) followed by radiation therapy.[28][Level of evidence A1]
Sources: 28 · Level of evidence A1
Two additional randomized trials, though not specifically designed to address the timing of radiation therapy and adjuvant chemotherapy, do add useful information. › In the NSABP-B-15 trial, patients who had undergone breast-conserving surgery received either one course of cyclophosphamide, methotrexate, and 5-FU (CMF) (n = 194) followed by radiation therapy followed by five additional cycles of CMF, or they received four cycles of doxorubicin and cyclophosphamide (n = 199) followed by radiation therapy.[28][Level of evidence A1]
No differences in DFS, distant DFS, and OS were observed between these two arms.
Two additional randomized trials, though not specifically designed to address the timing of radiation therapy and adjuvant chemotherapy, do add useful information.
The International Breast Cancer Study Group trials VI and VII also varied the timing of radiation therapy with CMF adjuvant chemotherapy and reported results similar to NSABP-B-15.[29]
Sources: 29
These studies showed that delaying radiation therapy for 2 to 7 months after surgery had no effect on the rate of local recurrence. These findings have been confirmed in a meta-analysis.[30][Level of evidence A1]
Sources: 30 · Level of evidence A1
In an unplanned analysis of patients treated on a phase III trial evaluating the benefit of adding trastuzumab in HER2-positive breast cancer patients, there was no associated increase in acute adverse events or frequency of cardiac events in patients who received concurrent adjuvant radiation therapy and trastuzumab.[31] Therefore, delivering radiation therapy concomitantly with trastuzumab appears to be safe and avoids additional delay in radiation therapy treatment initiation.
Sources: 31
Acute and Late Toxicities of Radiation Therapy
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Acute toxicities of radiation therapy include radiation dermatitis, breast swelling and/or itching, tightness in the axillary area, and fatigue. If regional nodes are being treated, patients can also experience nausea and a sore throat due to radiation esophagitis. Symptoms typically peak 1 to 2 weeks after radiation therapy, then decrease slowly over the next 4 to 6 weeks.[32]
Sources: 32
Late toxicities of radiation therapy are uncommon and can be minimized with radiation delivery techniques and with careful delineation of the target volume. Late effects of radiation include:
Radiation pneumonitis. In a retrospective analysis of 1,624 women treated with conservative surgery and adjuvant breast radiation at a single institution, the overall incidence of symptomatic radiation pneumonitis was 1.0% at a median follow-up of 77 months.[33] The incidence of pneumonitis increased to 3.0% with the use of a supraclavicular radiation field and to 8.8% when concurrent chemotherapy was administered. The incidence was only 1.3% in patients who received sequential chemotherapy.[33][Level of evidence C1]
Sources: 33 · 33 · Level of evidence C1
Cardiac events. Controversy existed as to whether adjuvant radiation therapy to the left chest wall or breast, with or without inclusion of the regional lymphatics, was associated with increased cardiac mortality. In women treated with radiation therapy before 1980, an increased cardiac death rate was noted after 10 to 15 years, compared with women with nonradiated or right-side-only radiated breast cancer.[24,34-36] This was probably caused by the radiation received by the left myocardium.Modern radiation therapy techniques introduced in the 1990s minimized deep radiation to the underlying myocardium when left-sided chest wall or left-breast radiation was used. Cardiac mortality decreased accordingly.[37,38]An analysis of the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program (SEER) data from 1973 to 1989 that reviewed deaths caused by ischemic heart disease in women who received breast or chest wall radiation showed that since 1980, no increased death rate resulting from ischemic heart disease in women who received left chest wall or breast radiation was found.[39,40][Level of evidence C1]A population-based case-control study evaluated major coronary events (i.e., myocardial infarction, coronary revascularization, or death from ischemic heart disease) in 2,168 women who underwent radiation therapy for breast cancer. The study found the overall average mean dose to the whole heart was 4.9 Gy (range, 0.03–27.72). The rates of major coronary events increased linearly with the mean dose to the heart by 7.4% per Gy (95% CI, 2.9%–14.5%; P < .001), with no apparent threshold.[41]
Sources: 24 · 34 · 36 · 37 · 38 · 39 · 40 · Level of evidence C1 · 41
Arm lymphedema. Lymphedema remains a major quality-of-life concern for breast cancer patients. Single-modality treatment of the axilla (surgery or radiation) is associated with a low incidence of arm edema. In patients who receive axillary dissection, adjuvant radiation therapy increases the risk of arm edema. Edema occurs in 2% to 10% of patients who receive axillary dissection alone compared with 13% to 18% of patients who receive axillary dissection and adjuvant radiation therapy.[42-44] For more information, see Lymphedema.
Sources: 42 · 44 · Lymphedema
Brachial plexopathy. Radiation injury to the brachial plexus after adjuvant nodal radiation therapy is a rare clinical entity for breast cancer patients. In a single-institution study using current radiation techniques, 449 breast cancer patients treated with postoperative radiation therapy to the breast and regional lymphatics were monitored for 5.5 years to assess the rate of brachial plexus injury.[45] The diagnosis of such injury was made clinically with computed tomography to distinguish radiation injury from tumor recurrence. When 54 Gy in 30 fractions was delivered to the regional nodes, the incidence of symptomatic brachial plexus injury was 1.0%, compared with 5.9% when increased fraction sizes (45 Gy in 15 fractions) were used.
Sources: 45
Contralateral breast cancer. One report suggested an increase in contralateral breast cancer for women younger than 45 years who received chest wall radiation therapy after mastectomy.[46] No increased risk of contralateral breast cancer occurred in women aged 45 years and older who received radiation therapy.[47] Techniques to minimize the radiation dose to the contralateral breast are used to keep the absolute risk as low as possible.[48]
Risk of second malignancy. The rate of second malignancy after adjuvant radiation therapy is very low. Sarcomas in the treated field are rare, with a long-term risk of 0.2% at 10 years.[49] In nonsmokers, the risk of lung cancer as a result of radiation exposure during treatment is minimal when current dosimetry techniques are used. Smokers, however, may have a small increased risk of lung cancer in the ipsilateral lung.[50]
Systemic Therapy for Stages I, II, and III Breast Cancer
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
The first decision about the use of systemic therapy in patients with stages I, II and III breast cancer is whether it should be given before or after surgery. This section outlines factors to consider when making this decision. Information about the treatment of locally advanced or inflammatory breast cancer is also included in this section.
Preoperative chemotherapy, also known as primary or neoadjuvant chemotherapy, has traditionally been given to patients with locally advanced breast cancer to reduce tumor volume and allow for definitive surgery. Treatment with preoperative chemotherapy can also allow for breast conservation therapy in patients who are not candidates for breast conservation at initial presentation. Preoperative chemotherapy may also reduce the need for an axillary lymph node dissection (ALND) in patients presenting with node-positive disease.
Much of the evidence presented in the following sections on preoperative chemotherapy is discussed in an American Society of Clinical Oncology guideline that describes the selection of options for the management of these patients.[1]
Sources: 1
A 2005 meta-analysis of multiple randomized clinical trials demonstrated that preoperative chemotherapy is associated with identical disease-free survival (DFS) and overall survival (OS) as the same therapy in the adjuvant setting.[2][Level of evidence A1]
Sources: 2 · Level of evidence A1
In 2019, the Early Breast Cancer Trialists’ Collaborative Group performed a meta-analysis using individual patient data from 4,756 women who participated in 10 trials that compared neoadjuvant chemotherapy with the same regimen given in the adjuvant setting.[3] Compared with adjuvant therapy, neoadjuvant therapy was associated with an increased frequency of breast conservation (65% vs. 49%). There were no differences between neoadjuvant chemotherapy and adjuvant therapy in distant recurrence, breast cancer mortality, or death from any cause. However, neoadjuvant therapy was associated with higher 15-year local recurrence rates (21.4% vs. 15.9%; relative risk [RR], 1.37; 95% confidence interval [CI], 1.17−1.61; P = .001).[3][Level of evidence A1]
Sources: 3 · 3 · Level of evidence A1
Pathological complete response (pCR) has been used as a surrogate end point for long-term outcomes, such as DFS, event-free survival (EFS), and OS, in preoperative clinical trials in breast cancer. A pooled analysis (CTNeoBC) of 11 preoperative randomized trials (n = 11,955) determined that pCR, defined as no residual invasive cancer in the breast and axillary nodes with presence or absence of in situ cancer (ypT0/is ypN0 or ypT0 ypN0), was associated with improved outcomes compared with eradication of invasive tumor from the breast alone (ypT0/is).[4] pCR could not be validated in this study as a surrogate end point for improved EFS and OS.[4][Level of evidence C2] Because of a strong association between pCR and substantially improved outcomes in individual patients with more aggressive subtypes of breast cancer, the U.S. Food and Drug Administration (FDA) has supported use of pCR as an end point in preoperative clinical trials for patients with high-risk, early-stage breast cancer.
Sources: 4 · 4 · Level of evidence C2
Unfortunately, categorizing patients as having pCR or residual disease offers no distinction among patients with varied amounts of residual disease. The residual cancer burden (RCB) method was designed to address this and other prognostic deficits. The RCB method provides a standard to evaluate and quantify the extent of residual disease in breast and axillary lymph nodes following neoadjuvant chemotherapy. It is reported as a continuous score, with pCR being scored as RCB-0. There are four RCB classes ranging from RCB-0 to RCB-3. Determining RCB after neoadjuvant treatment has been validated as a prognostic predictor in early breast cancer.
A pooled, multinational, multi-institutional analysis was performed, using participant-level RCB results and clinicopathological data. Data from 5,161 patients were analyzed to assess the association between the continuous RCB score and the primary study outcome, EFS. With a median follow-up of 56 months, the RCB score was prognostic within each breast cancer subtype, with a higher RCB score significantly associated with worse EFS. RCB score was prognostic for EFS in multivariable models adjusted for age, grade, T (tumor) category, and nodal status at baseline. The adjusted hazard ratio (HR) associated with a one-unit increase in RCB ranged from 1.52 in the HER2-negative hormone receptor–positive group to 2.09 in the HER2-positive hormone receptor–negative group (P < .0001 for all subtypes).[5]
Sources: 5
Neoadjuvant therapy is particularly favored in patients with triple-negative or HER2-positive disease, when pathological response is used as a guide in choosing the optimal adjuvant therapy after surgery. For more information, see the sections on Stages I, II, and III Triple-Negative Breast Cancer and Stages I, II, and III HER2-Positive Breast Cancer.
Sources: Stages I, II, and III Triple-Negative Breast Cancer · Stages I, II, and III HER2-Positive Breast Cancer
Omission of postoperative radiation therapy to the regional nodes in patients who initially present as node positive and become node negative after neoadjuvant therapy is currently being evaluated.
Patient Selection, Staging, Treatment, and Follow-Up
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Multidisciplinary management of patients undergoing preoperative therapy by an experienced team is essential to optimize the following:
Patient selection.
Choice of systemic therapy.
Management of the axilla and surgical approach.
Decision to administer adjuvant radiation therapy.
The tumor histology, grade, and hormone receptor status are carefully evaluated before preoperative therapy is initiated. Patients whose tumors have a pure lobular histology, low grade, or high hormone receptor expression and HER2-negative status are less likely to respond to chemotherapy and should consider primary surgery, especially if the nodes are clinically negative. Even if adjuvant chemotherapy is given after surgery in these cases, a third-generation regimen (anthracycline/taxane based) may be avoided.
Before beginning preoperative therapy, the extent of the disease within the breast and regional lymph nodes should be assessed. Staging of systemic disease may include:[6]
Sources: 6
Computed tomography scan of the chest and abdomen and a bone scan.
Positron emission tomography.
When breast-conserving therapy is desired, baseline breast imaging is performed to identify the tumor location and exclude multicentric disease. Suspicious abnormalities are usually biopsied before beginning treatment, and a marker is placed at the center of the breast tumor(s). When possible, suspicious axillary nodes should be biopsied before initiation of systemic treatment.
In patients with clinically negative nodes who receive neoadjuvant chemotherapy, a sentinel lymph node (SLN) biopsy is typically performed at the time of surgery. In patients presenting with positive lymph nodes, detected by either clinical examination or imaging, SLN biopsy may be performed in a patient who becomes clinically node negative after preoperative therapy.[7] The use of dual mapping with both radiocolloid and blue dye and retrieval of at least three negative lymph nodes was associated with a lower false-negative rate and ALND may be omitted in these patients.[8][Level of evidence B4]; [9][Level of evidence C2]; [10][Level of evidence C3]
Sources: 7 · 8 · Level of evidence B4 · 9 · Level of evidence C2 · 10 · Level of evidence C3
When considering preoperative therapy, treatment options include:
For HER2-negative breast tumors, an anthracycline/taxane-based chemotherapy regimen.
For HER2-positive disease, chemotherapy and HER2-targeted therapy.
Ideally, the entire treatment regimen is administered before surgery.
For postmenopausal women with hormone receptor–positive breast cancer, chemotherapy is an option. For those who cannot be given chemotherapy, preoperative endocrine therapy may be an option.
For premenopausal women with hormone-responsive cancer, the use of preoperative endocrine therapy is under investigation.
Regular clinical assessment of response to therapy is necessary after beginning preoperative therapy. Repeat radiographic assessment is also required if breast conservation is the surgical goal. Patients with progressive disease during preoperative therapy may either transition to a non–cross-resistant regimen or proceed to surgery, if feasible.[11,12] Although switching to a non–cross-resistant regimen results in a higher pCR rate than continuing the same therapy, there is no clear evidence that other breast cancer outcomes are improved with this approach.
Stages I, II, and III HER2-Negative Hormone Receptor–Positive Breast Cancer
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Most studies that support the use of chemotherapy were conducted after patients had surgery and prior to the widespread use of preoperative therapy. In general, their results are still applicable to preoperative treatment, and these regimens are the ones most commonly used in the neoadjuvant space for this subtype. The following section describes studies that examined the use of chemotherapy in the preoperative setting.
Early trials examined whether anthracycline-based regimens used in the adjuvant setting would prolong DFS and OS when used in the preoperative setting. The evidence supports higher rates of breast-conserving therapy with the use of a preoperative anthracycline chemotherapy regimen than with postoperative use, but no improvement in survival was noted with the preoperative strategy.
Typically, an anthracycline-and-taxane–based regimen is used if chemotherapy is administered in the neoadjuvant setting for patients with HER2-negative breast cancer.
Evidence (anthracycline/taxane–based chemotherapy regimen):
In an effort to improve on the results observed with doxorubicin and cyclophosphamide (AC) alone, the NSABP B-27 trial (NCT00002707) was conducted. Patients were randomly assigned to receive (1) four cycles of preoperative AC followed by surgery, (2) four cycles of AC followed by four cycles of docetaxel and then surgery, or (3) four cycles of AC followed by surgery and then four cycles of docetaxel.[13][Level of evidence B1]
Sources: NSABP B-27 · 13 · Level of evidence B1
In an effort to improve on the results observed with doxorubicin and cyclophosphamide (AC) alone, the NSABP B-27 trial (NCT00002707) was conducted. Patients were randomly assigned to receive (1) four cycles of preoperative AC followed by surgery, (2) four cycles of AC followed by four cycles of docetaxel and then surgery, or (3) four cycles of AC followed by surgery and then four cycles of docetaxel.[13][Level of evidence B1]
The administration of preoperative AC followed by docetaxel was associated with a higher clinical complete response rate compared with the administration of AC alone (63.6% for AC followed by docetaxel and 40.1% for AC alone; P < .001); a higher pCR rate was also observed (26.1% for AC followed by docetaxel and 13.7% for AC alone; P < .001).
Data from NSABP B-27 and the Aberdeen Breast Group Trial support the use of anthracycline/taxane–based regimens in women with initial response or with relative resistance to anthracyclines.[11]
Sources: 11
Alternative anthracycline/taxane schedules have also been evaluated (concurrent docetaxel, doxorubicin, and cyclophosphamide) and appear similar in efficacy to the sequential approach described above.[14][Level of evidence B3]
Sources: 14 · Level of evidence B3
The phase III GeparSepto trial (NCT01583426) investigated an alternative taxane (nab-paclitaxel) in patients with untreated primary breast cancer.[15] Patients (n = 1,229) were randomly assigned to receive 12 weeks of nab-paclitaxel or paclitaxel followed by epirubicin and cyclophosphamide for four cycles.
Sources: GeparSepto · 15
The phase III GeparSepto trial (NCT01583426) investigated an alternative taxane (nab-paclitaxel) in patients with untreated primary breast cancer.[15] Patients (n = 1,229) were randomly assigned to receive 12 weeks of nab-paclitaxel or paclitaxel followed by epirubicin and cyclophosphamide for four cycles.
The pCR rate was higher in the nab-paclitaxel arm (233 patients, 38%; 95% CI, 35%–42%) when compared with the paclitaxel arm (174 patients, 29%; 95% CI, 25%–33%).[15][Level of evidence B3]
Sources: 15 · Level of evidence B3
However, in the ETNA trial (NCT01822314) that compared neoadjuvant nab-paclitaxel with paclitaxel followed by anthracycline-based therapy, no significant difference in pCR was observed, and neutropenia and peripheral neuropathy were more frequent in the nab-paclitaxel arm.[16]
Differences in taxane dose and schedule may explain the different findings in the GeparSepto and ETNA trials.
The incorporation of other cytotoxic agents to anthracycline/taxane–based regimens has not offered a significant additional benefit to breast conservation or pCR rate in unselected breast cancer populations.[17][Level of evidence B3]
Sources: 17 · Level of evidence B3
Preoperative endocrine therapy for HER2-negative hormone receptor–positive breast cancer
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Preoperative endocrine therapy may be an option for postmenopausal women with hormone receptor–positive breast cancer when chemotherapy is not a suitable option because of comorbidities or performance status. Although the toxicity profile of preoperative hormonal therapy over the course of 3 to 6 months is favorable, the pCR rates obtained (1%–8%) are far lower than have been reported with chemotherapy in unselected populations.[18][Level of evidence B3]
Sources: 18 · Level of evidence B3
Longer duration of preoperative therapy may be required in this patient population. Preoperative tamoxifen was associated with an overall response rate of 33%, with maximum response occurring up to 12 months after therapy in some patients.[19] A randomized study of 4, 8, or 12 months of preoperative letrozole in older patients who were not fit for chemotherapy indicated that the longer duration of therapy resulted in the highest pCR rate (17.5% vs. 5% vs. 2.5%, P-value for trend < .04).[20][Level of evidence B3]
Sources: 19 · 20 · Level of evidence B3
Aromatase inhibitors (AIs) have also been compared with tamoxifen in the preoperative setting. Overall objective response and breast-conserving therapy rates with 3 to 4 months of preoperative therapy were either statistically significantly improved in the AI-treated women [18] or comparable to tamoxifen-associated outcomes.[20]
The use of preoperative endocrine therapy in premenopausal women with hormone-responsive breast cancer remains investigational.
Postoperative systemic therapy for HER2-negative hormone receptor–positive breast cancer
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Stage and molecular features determine the need for adjuvant systemic therapy and the choice of modalities for patients who have not been treated with preoperative systemic therapy. The selection of therapy is most appropriately based on knowledge of an individual’s risk of tumor recurrence balanced against the short-term and long-term risks of adjuvant treatment. This approach allows clinicians to help individuals determine if the gains anticipated from treatment are reasonable for their situation.
Anthracycline-containing chemotherapy
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
An Early Breast Cancer Trialists' Collaborative Group (EBCTCG) meta-analysis included 11 trials that began from 1976 to 1989 in which women were randomly assigned to receive regimens containing anthracyclines (e.g., doxorubicin or epirubicin) or CMF (cyclophosphamide, methotrexate, and fluorouracil [5-FU]). The result of the overview analysis comparing CMF and anthracycline-containing regimens suggested a slight advantage for the anthracycline regimens in both premenopausal and postmenopausal women. The HER2 status of the women in these trials was unknown.[21]
Sources: 21
Several trials have addressed the benefit of adding a taxane (paclitaxel or docetaxel) to an anthracycline-based adjuvant chemotherapy regimen.[22-26]
A literature-based meta-analysis of 13 studies demonstrated that the inclusion of a taxane improved both DFS and OS (DFS: HR, 0.83; 95% CI, 0.79–0.87; P < .001; OS: HR, 0.85; 95% CI, 0.79–0.91; P < .001). Five-year absolute survival differences were 5% for DFS and 3% for OS, in favor of taxane-containing regimens.[22][Level of evidence A1]
Sources: 22 · Level of evidence A1
A number of studies have addressed the optimal chemotherapy schedule and taxane selection.
An Eastern Cooperative Oncology Group–led intergroup trial (E1199 [NCT00004125]) involving 4,950 patients compared, in a factorial design, two schedules (weekly and every 3 weeks) of the two drugs (docetaxel vs. paclitaxel) after standard-dose AC chemotherapy given every 3 weeks.[27][Level of evidence A1] Study findings include the following:
Sources: E1199 · 27 · Level of evidence A1
There was no difference observed in the overall comparison of docetaxel to paclitaxel with regard to DFS (odds ratio [OR], 1.03; 95% CI, 0.91–1.16; P = .61) or between the 1-week and 3-week schedules (OR, 1.06; 95% CI, 0.94–1.20; P = .33).
There was a significant association between the drug administered and schedule for both DFS (0.003) and OS (0.01). Thus, compared with paclitaxel given every 3 weeks, paclitaxel given weekly improved both DFS (OR, 1.27; 95% CI, 1.01–1.57; P = .006) and OS (OR, 1.32; 95% CI, 1.02–1.72; P = .01).
Docetaxel given every 3 weeks was also superior in DFS to paclitaxel given every 3 weeks (OR, 1.23; 95% CI, 1.00–1.52; P = .02), but the difference was not statistically significant for OS (OR, 1.13; 95% CI, 0.88–1.46; P = .25).
Docetaxel given weekly was not superior to paclitaxel given every 3 weeks. There was no stated a priori basis for expecting that varying the schedule of administration would have opposite effects for the two drugs.
Several studies sought to determine whether decreasing the duration between chemotherapy cycles could improve clinical outcomes. The overall results of these studies support the use of dose-dense chemotherapy for women with HER2-negative breast cancer.
Evidence (administration of dose-dense chemotherapy in women with HER2-negative breast cancer):
A U.S. intergroup trial (CALGB-9741 [NCT00003088]) of 2,005 node-positive patients compared, in a 2 × 2 factorial design, the use of concurrent AC followed by paclitaxel with sequential doxorubicin, paclitaxel, and cyclophosphamide given every 2 weeks with filgrastim or every 3 weeks.[28][Level of evidence A1]
Sources: CALGB-9741 · 28 · Level of evidence A1
A U.S. intergroup trial (CALGB-9741 [NCT00003088]) of 2,005 node-positive patients compared, in a 2 × 2 factorial design, the use of concurrent AC followed by paclitaxel with sequential doxorubicin, paclitaxel, and cyclophosphamide given every 2 weeks with filgrastim or every 3 weeks.[28][Level of evidence A1]
At a median follow-up of 68 months, dose-dense treatment improved DFS, the primary end point, in all patient populations (HR, 0.80; P = .018), but not OS (HR, 0.85; P = .12).[29][Level of evidence A1]
Sources: 29 · Level of evidence A1
There was no interaction between density and sequence.
Severe neutropenia was less frequent in patients who received the dose-dense regimens.[30][Level of evidence A1]
Sources: 30 · Level of evidence A1
An Italian trial (NCT00433420) compared two versus three weekly doses of epirubicin plus cyclophosphamide (with or without 5-FU) in a factorial design, with a result similar to a U.S. intergroup trial; however, this trial also demonstrated a difference in OS.[31]
Sources: NCT00433420 · 31
An Italian trial (NCT00433420) compared two versus three weekly doses of epirubicin plus cyclophosphamide (with or without 5-FU) in a factorial design, with a result similar to a U.S. intergroup trial; however, this trial also demonstrated a difference in OS.[31]
For the dose-density comparison, the 5-year DFS rate was 81% (95% CI, 79%–84%) in patients treated every 2 weeks and 76% (95% CI, 74%–79%) in patients treated every 3 weeks (HR, 0.77; 95% CI, 0.65–0.92; P = .004).
Five-year OS rates were 94% (95% CI, 93%–96%) and 89% (95% CI, 87%–91%; HR, 0.65; 0.51–0.84; P = .001).[31][Level of evidence A1]
Sources: 31 · Level of evidence A1
A meta-analysis of 26 randomized trials that included 37,298 women treated with anthracycline- and taxane-containing chemotherapy compared standard regimens (given every 3–4 weeks) with more dose-intense regimens. Regimens that increased dose intensity by shortening the interval between cycles (i.e., dose-dense therapy or administration of the same dose over a shorter time period) and regimens that increased dose intensity by administering individual drugs in sequence to allow for higher doses (i.e., sequential scheduling).[32]
Sources: 32
A meta-analysis of 26 randomized trials that included 37,298 women treated with anthracycline- and taxane-containing chemotherapy compared standard regimens (given every 3–4 weeks) with more dose-intense regimens. Regimens that increased dose intensity by shortening the interval between cycles (i.e., dose-dense therapy or administration of the same dose over a shorter time period) and regimens that increased dose intensity by administering individual drugs in sequence to allow for higher doses (i.e., sequential scheduling).[32]
Patients who received more dose-intense regimens had superior recurrence-free survival (RFS) (28.0% vs. 31.4%; RR, 0.86; 95% CI, 0.82–0.89; P < .0001) and OS (18.9% vs. 21.3%; RR, 0.87; 95% CI, 0.83–0.92; P < .0001) at 10 years. The difference was present and statistically significant in receptor-positive and receptor-negative subgroups.
Non–anthracycline-containing regimens
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Because of potential long-term toxicities from anthracyclines, the efficacy and toxicity of non–anthracycline-containing regimens have been studied. For more information, see the Toxicity of Adjuvant Chemotherapy section.
Sources: Toxicity of Adjuvant Chemotherapy
Data are inconsistent regarding whether an anthracycline-containing regimen is more efficacious than a non–anthracycline-containing regimen. Both types of regimens are acceptable, and the choice must be individualized on the basis of risk and other patient characteristics.
Evidence (non–anthracycline-containing regimens):
The ABC trials were three open-label, randomized, phase III trials comparing TC (taxane and cyclophosphamide) with regimens containing an anthracycline/cyclophosphamide plus a taxane (TaxAC) for the adjuvant treatment of patients with HER2-negative early-stage breast cancer.[33] The three trials were analyzed together with a primary end point of invasive disease-free survival (IDFS). The primary aim was to determine if TC (the non-anthracycline arm) was noninferior to the TaxAC arms. Inferiority for TC was predefined as an HR exceeding 1.18 for the TC versus TaxAC arms. Participants were randomly assigned to receive TC (n = 2, 125) or TaxAC (n = 2,127).
Sources: 33
The ABC trials were three open-label, randomized, phase III trials comparing TC (taxane and cyclophosphamide) with regimens containing an anthracycline/cyclophosphamide plus a taxane (TaxAC) for the adjuvant treatment of patients with HER2-negative early-stage breast cancer.[33] The three trials were analyzed together with a primary end point of invasive disease-free survival (IDFS). The primary aim was to determine if TC (the non-anthracycline arm) was noninferior to the TaxAC arms. Inferiority for TC was predefined as an HR exceeding 1.18 for the TC versus TaxAC arms. Participants were randomly assigned to receive TC (n = 2, 125) or TaxAC (n = 2,127).
In an interim futility analysis, the HR for IDFS was 1.202 (95% CI, 0.97–1.49) for TC versus TaxAC, which exceeded the predetermined limit to define TC as inferior.
The 4-year IDFS rate was 88.2% for patients who received TC and 90.7% for patients who received TaxAC (P = .04).
Although the findings favored treatment with regimens containing an anthracycline/cyclophosphamide plus a taxane, absolute differences between TC and TaxAC were small. Exploratory analyses suggested the greatest benefits from the TaxAC regimens were seen in patients with triple-negative disease and hormone receptor–positive disease with involved axillary lymph nodes, supporting a role for non–anthracycline-containing regimens in patients with lower-risk disease.
The West German Plan B trial (NCT01049425) randomly assigned 2,499 women with node-positive or high-risk node-negative disease to receive either four cycles of epirubicin/cyclophosphamide plus four cycles of docetaxel (EC-T) or six cycles of TC.[34] After an early amendment, women with hormone receptor–positive disease and a recurrence score below 12 were excluded.
The West German Plan B trial (NCT01049425) randomly assigned 2,499 women with node-positive or high-risk node-negative disease to receive either four cycles of epirubicin/cyclophosphamide plus four cycles of docetaxel (EC-T) or six cycles of TC.[34] After an early amendment, women with hormone receptor–positive disease and a recurrence score below 12 were excluded.
After a median follow-up of 60 months, 5-year outcomes were similar in the EC-T and TC arms for DFS (HR, 1.004; 95% CI, 0.776–1.299) and OS (HR, 0.937; 95% CI, 0.654–1.342).[34][Level of evidence B1]
Sources: 34 · Level of evidence B1
The upper 90% confidence limit for DFS did not exceed the noninferiority boundary of 1.467.
There were five treatment-related deaths among patients who received TC and one death among those who received EC-T, but symptomatic adverse events were more frequent in patients who received EC-T.
Timing of postoperative chemotherapy
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
The optimal time to initiate adjuvant therapy is uncertain. Studies have reported the following:
A retrospective, observational, single-institution study of patients with early-stage breast cancer who were diagnosed between 1997 and 2011 revealed that delays in initiation of adjuvant chemotherapy adversely affected survival outcomes.[35][Level of evidence C1]
Sources: 35 · Level of evidence C1
A retrospective, observational, single-institution study of patients with early-stage breast cancer who were diagnosed between 1997 and 2011 revealed that delays in initiation of adjuvant chemotherapy adversely affected survival outcomes.[35][Level of evidence C1]
Initiation of chemotherapy 61 days or more after surgery was associated with adverse outcomes among patients with stage II breast cancer (distant RFS [DRFS]: HR, 1.20; 95% CI, 1.02–1.43) and stage III breast cancer (OS: HR, 1.76; 95% CI, 1.26–2.46; RFS: HR, 1.34; 95% CI, 1.01–1.76; and DRFS: HR, 1.36; 95% CI, 1.02–1.80).
Patients with triple-negative breast cancer (TNBC) and those with HER2-positive tumors treated with trastuzumab who started chemotherapy 61 days or more after surgery had worse survival (TNBC: HR, 1.54; 95% CI, 1.09–2.18; HER2-positive: HR, 3.09; 95% CI, 1.49–6.39) than did those who initiated treatment in the first 30 days after surgery.
Because of the weaknesses and limitations of this study design, the optimal time to initiate adjuvant chemotherapy remains uncertain.
A population-based study from California included 24,843 patients and found that delays in initiating adjuvant chemotherapy of 90 days or less had no impact on OS, but found a substantial effect for delays over 90 days (HR, 1.27; 95% CI, 1.05–1.53), particularly among patients with TNBC.[36][Level of evidence C1]
Sources: 36 · Level of evidence C1
Multiple other studies have examined the effect of treatment delays of 90 days or less and have reported inconsistent results, with the possible exception of patients with TNBC.[36]
Sources: 36
Endocrine therapy
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Much of the evidence presented in the following sections on therapy for women with hormone receptor–positive disease has been considered in an American Society of Clinical Oncology guideline that describes several options for the management of these patients.[37] Five years of adjuvant endocrine therapy has been shown to substantially reduce the risks of locoregional and distant recurrence, contralateral breast cancer, and death from breast cancer.
Sources: 37
The optimal duration of endocrine therapy is unclear, with the preponderance of evidence supporting at least 5 years of endocrine therapy. A meta-analysis of 88 clinical trials involving 62,923 women with hormone receptor–positive breast cancer who were disease free after 5 years of endocrine therapy showed a steady risk of late recurrence 5 to 20 years after diagnosis.[38][Level of evidence C2] The risk of distant recurrence correlated with the original tumor (T) and node (N) status, with risks ranging from 10% to 41%.
Sources: 38 · Level of evidence C2
Tamoxifen
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Tamoxifen has been shown to benefit women with hormone receptor–positive breast cancer.
Evidence (tamoxifen for hormone receptor–positive early breast cancer):
The EBCTCG performed a meta-analysis of systemic treatment of early breast cancer by hormone, cytotoxic, or biological therapy methods in randomized trials involving 144,939 women with stage I or stage II breast cancer. An analysis published in 2005 included information on 80,273 women in 71 trials of adjuvant tamoxifen.[21][Level of evidence A1]
Sources: 21 · Level of evidence A1
The EBCTCG performed a meta-analysis of systemic treatment of early breast cancer by hormone, cytotoxic, or biological therapy methods in randomized trials involving 144,939 women with stage I or stage II breast cancer. An analysis published in 2005 included information on 80,273 women in 71 trials of adjuvant tamoxifen.[21][Level of evidence A1]
In this analysis, the benefit of tamoxifen was found to be restricted to women with hormone receptor–positive or hormone receptor–unknown breast tumors. In these women, the 15-year absolute reduction associated with 5 years of use was 12% for recurrence and 9% for mortality.
Allocation to approximately 5 years of adjuvant tamoxifen reduces the annual breast cancer death rate by 31%, largely irrespective of the use of chemotherapy, age (<50 years, 50–69 years, ≥70 years), progesterone receptor (PR) status, or other tumor characteristics.
The meta-analysis also confirmed the benefit of adjuvant tamoxifen in hormone receptor–positive premenopausal women. Women younger than 50 years obtained a degree of benefit from 5 years of tamoxifen similar to that obtained by older women. In addition, the proportional reductions in both recurrence and mortality associated with tamoxifen use were similar in women with either node-negative or node-positive breast cancer, but the absolute improvement in survival at 10 years was greater in the node-positive breast cancer group (5.3% vs. 12.5% with 5 years of use).
Similar results were found in the IBCSG-13-93 trial.[39] Of 1,246 women with stage II disease, only the women with hormone receptor–positive disease benefited from tamoxifen.
Sources: 39
The optimal duration of tamoxifen use has been addressed by the EBCTCG meta-analysis and by several large randomized trials.[21,40-43] Ten years of tamoxifen therapy has shown superiority to shorter durations of tamoxifen therapy.
Evidence (duration of tamoxifen therapy):
The EBCTCG meta-analysis demonstrated that 5 years of tamoxifen was superior to shorter durations. The following results were reported:[21]
Sources: 21
The EBCTCG meta-analysis demonstrated that 5 years of tamoxifen was superior to shorter durations. The following results were reported:[21]
A highly significant advantage of 5 years versus 1 to 2 years of tamoxifen with respect to the risk of recurrence (proportionate reduction, 15.2%; P < .001) and a less significant advantage with respect to mortality (proportionate reduction, 7.9%; P = .01) was observed.
Long-term follow-up of the Adjuvant Tamoxifen Longer Against Shorter (ATLAS [NCT00003016]) trial demonstrated that 10 years of tamoxifen therapy was superior to 5 years of tamoxifen therapy. Between 1996 and 2005, 12,894 women with early breast cancer were randomly assigned to receive 10 years or 5 years of tamoxifen therapy. The following results were reported:[43][Level of evidence A1]The results of the ATLAS trial indicated that for women who remained premenopausal after 5 years of adjuvant tamoxifen, continued tamoxifen for 5 more years was beneficial.[43] Women who have become menopausal after 5 years of tamoxifen may also be treated with AIs. For more information, see the Aromatase inhibitors section.
Sources: ATLAS · 43 · Level of evidence A1 · 43 · Aromatase inhibitors
Long-term follow-up of the Adjuvant Tamoxifen Longer Against Shorter (ATLAS [NCT00003016]) trial demonstrated that 10 years of tamoxifen therapy was superior to 5 years of tamoxifen therapy. Between 1996 and 2005, 12,894 women with early breast cancer were randomly assigned to receive 10 years or 5 years of tamoxifen therapy. The following results were reported:[43][Level of evidence A1]The results of the ATLAS trial indicated that for women who remained premenopausal after 5 years of adjuvant tamoxifen, continued tamoxifen for 5 more years was beneficial.[43] Women who have become menopausal after 5 years of tamoxifen may also be treated with AIs. For more information, see the Aromatase inhibitors section.
Study results revealed that 10 years of tamoxifen reduced the risk of breast cancer recurrence (617 recurrences for 10 years of tamoxifen vs. 711 recurrences for 5 years of tamoxifen; P = .002), reduced breast cancer mortality (331 deaths for 10 years of tamoxifen vs. 397 deaths for 5 years of tamoxifen; P = .01), and reduced overall mortality (639 deaths for 10 years of tamoxifen vs. 722 deaths for 5 years of tamoxifen; P = .01).
Of note, from the time of the original breast cancer diagnosis, the benefits of 10 years of therapy were less extreme before than after year 10. At 15 years from the time of diagnosis, breast cancer mortality was 15% at 10 years and 12.2% at 5 years.
Compared with 5 years, 10 years of tamoxifen therapy increased the risk of the following:
Long-term follow-up of the Adjuvant Tamoxifen Longer Against Shorter (ATLAS [NCT00003016]) trial demonstrated that 10 years of tamoxifen therapy was superior to 5 years of tamoxifen therapy. Between 1996 and 2005, 12,894 women with early breast cancer were randomly assigned to receive 10 years or 5 years of tamoxifen therapy. The following results were reported:[43][Level of evidence A1]The results of the ATLAS trial indicated that for women who remained premenopausal after 5 years of adjuvant tamoxifen, continued tamoxifen for 5 more years was beneficial.[43] Women who have become menopausal after 5 years of tamoxifen may also be treated with AIs. For more information, see the Aromatase inhibitors section. › Compared with 5 years, 10 years of tamoxifen therapy increased the risk of the following:
Pulmonary embolus: RR, 1.87 (95% CI, 1.13–3.07; P = .01).
Stroke: RR, 1.06 (95% CI, 0.83–1.36).
Ischemic heart disease: RR, 0.76 (95% CI, 0.6–0.95; P = .02).
Endometrial cancer: RR, 1.74 (95% CI, 1.30–2.34; P = .0002). Notably, the cumulative risk of endometrial cancer during years 5 to 14 from breast cancer diagnosis was 3.1% for women who received 10 years of tamoxifen versus 1.6% for women who received 5 years of tamoxifen. The mortality for years 5 to 14 was 12.2 versus 15 for an absolute mortality reduction of 2.8%.
Tamoxifen and chemotherapy
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Ovarian ablation, tamoxifen, and chemotherapy
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Evidence suggests ovarian ablation alone is not an effective substitute for other systemic therapies.[45-49] Further, the addition of ovarian ablation to chemotherapy and/or tamoxifen has not been found to significantly improve outcomes.[47,49-52]
Evidence (tamoxifen plus ovarian suppression):
The largest study (SOFT [NCT00066690]) to examine the addition of ovarian ablation to tamoxifen with or without chemotherapy randomly assigned 2,033 premenopausal women (53% of whom had received previous chemotherapy) to receive tamoxifen or tamoxifen plus ovarian suppression with triptorelin or ablation with surgery or radiation therapy.[53][Level of evidence B1]
Sources: SOFT · 53 · Level of evidence B1
The largest study (SOFT [NCT00066690]) to examine the addition of ovarian ablation to tamoxifen with or without chemotherapy randomly assigned 2,033 premenopausal women (53% of whom had received previous chemotherapy) to receive tamoxifen or tamoxifen plus ovarian suppression with triptorelin or ablation with surgery or radiation therapy.[53][Level of evidence B1]
Upon initial report, with a median follow-up of 5.6 years, there was no significant difference in the primary outcome of DFS (HR, 0.83; 95% CI, 0.66–1.04; P = .10); the 5-year DFS rate was 86% in the tamoxifen-plus-ovarian-suppression group versus 84.7% in the tamoxifen-alone group. However, updated results with a median follow-up of 8 years, demonstrated improved DFS with tamoxifen plus ovarian suppression compared with tamoxifen alone (HR, 0.76; 95% CI, 0.62–0.93; P = .009); the 8-year DFS rate was 83.2% in the tamoxifen-plus-ovarian-suppression group versus 78.9% in the tamoxifen-alone group.
In addition, OS at 8 years was improved with tamoxifen plus ovarian suppression compared with tamoxifen alone (HR, 0.67; 95% CI, 0.48–0.92; P = .01); the 8-year OS rate was 93.3% in the tamoxifen-plus-ovarian-suppression group versus 91.5% in the tamoxifen-alone group.Despite overall negative initial results, subgroup analysis suggested a benefit with ovarian suppression in women who underwent chemotherapy and remained premenopausal afterwards. Follow-up results at 8 years, however, did not demonstrate heterogeneity of treatment effect according to whether chemotherapy was administered, although recurrences were more frequent among patients who received chemotherapy.[54]
Sources: 54
A Korean Breast Cancer Study Group trial (NCT00912548) included 1,293 premenopausal women younger than 45 years, all of whom had received adjuvant chemotherapy and either retained ovarian function or regained it after 2 years of tamoxifen. Patients were randomly assigned to receive either ovarian function suppression with goserelin plus tamoxifen or tamoxifen alone.[55]
Sources: NCT00912548 · 55
A Korean Breast Cancer Study Group trial (NCT00912548) included 1,293 premenopausal women younger than 45 years, all of whom had received adjuvant chemotherapy and either retained ovarian function or regained it after 2 years of tamoxifen. Patients were randomly assigned to receive either ovarian function suppression with goserelin plus tamoxifen or tamoxifen alone.[55]
In the intent-to-treat analysis of 1,282 patients, the 5-year DFS rate was 89.8% for patients in the goserelin-plus-tamoxifen group and 87.3% for patients in the tamoxifen-alone group (HR, 0.69; 95% CI, 0.49–0.98; P = .036).
OS was a secondary end point and was also improved for patients in the goserelin-plus-tamoxifen group (HR, 0.31; 95% CI, 0.10–0.95; P = .039).[55][Level of evidence A1]
Sources: 55 · Level of evidence A1
Aromatase inhibitors
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Premenopausal women
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
AIs have been compared with tamoxifen in premenopausal women in whom ovarian function was suppressed or ablated. The results of these studies have been conflicting.
Evidence (comparison of an AI with tamoxifen in premenopausal women):
In one study (NCT00295646), 1,803 women who received goserelin were randomly assigned to a 2 × 2 factorial design trial that compared anastrozole and tamoxifen, with or without zoledronic acid.[56]
Sources: NCT00295646 · 56
In one study (NCT00295646), 1,803 women who received goserelin were randomly assigned to a 2 × 2 factorial design trial that compared anastrozole and tamoxifen, with or without zoledronic acid.[56]
At a median follow-up of 62 months, there was no difference in DFS (HR, 1.08; 95% CI, 0.81–1.44; P = .59).
OS was superior with tamoxifen (HR, 1.75; 95% CI, 1.08–2.83; P = .02).
In two unblinded studies that were analyzed together (TEXT [NCT00066703] and SOFT [NCT00066690]), exemestane was also compared with tamoxifen in 4,690 premenopausal women who underwent ovarian ablation.[57]
In two unblinded studies that were analyzed together (TEXT [NCT00066703] and SOFT [NCT00066690]), exemestane was also compared with tamoxifen in 4,690 premenopausal women who underwent ovarian ablation.[57]
The use of exemestane resulted in a significant difference in DFS. The 8-year DFS rate was 86.8% in the exemestane-ovarian suppression group vs. 82.8% in the tamoxifen-ovarian suppression group (HR, 0.77; 95% CI, 0.67–0.90; P < .001).[57][Level of evidence B1]
Sources: 57 · Level of evidence B1
The 8-year rate of freedom from distant recurrence was also higher in the exemestane-ovarian suppression group (91.8% vs. 89.7%; HR, 0.80; 95% CI, 0.66–0.96; P = .02).
Despite improvements in DFS and freedom from distant recurrence, no difference in OS was observed in the exemestane-ovarian suppression group compared with the tamoxifen-ovarian suppression group (93.4% vs. 93.3%; HR, 0.98; 95% CI, 0.79–1.22; P = .84).[57][Level of evidence A1] However, after a median follow-up of 12 years in the SOFT trial, the 12-year OS rate was 89.4% in the exemestane-ovarian suppression group and 86.8% in a tamoxifen-alone group from that study (HR, 0.80; 95% CI, 0.62–1.04).[58]
Sources: 57 · Level of evidence A1 · 58
A follow-up report on the differences in quality of life (QOL) for the exemestane-ovarian suppression group versus the tamoxifen-ovarian suppression group observed the following results (the differences cited below were all significant at P < .001 and occurred in patients who did and did not receive chemotherapy):[59]
Sources: 59
In two unblinded studies that were analyzed together (TEXT [NCT00066703] and SOFT [NCT00066690]), exemestane was also compared with tamoxifen in 4,690 premenopausal women who underwent ovarian ablation.[57] › A follow-up report on the differences in quality of life (QOL) for the exemestane-ovarian suppression group versus the tamoxifen-ovarian suppression group observed the following results (the differences cited below were all significant at P < .001 and occurred in patients who did and did not receive chemotherapy):[59]
Patients who received tamoxifen plus ovarian function suppression were more affected by hot flashes and sweats over 5 years than were those who received exemestane plus ovarian function suppression, although these symptoms improved.
Patients who received exemestane plus ovarian function suppression reported more vaginal dryness, greater loss of sexual interest, and more difficulties becoming aroused than did patients who received tamoxifen plus ovarian function suppression. These differences persisted over time.
An increase in bone or joint pain was more pronounced, particularly in the short term, in patients who received exemestane plus ovarian function suppression than in patients who received tamoxifen plus ovarian function suppression.
Changes in global QOL indicators from baseline were small and similar between treatments over the 5 years.[59][Level of evidence A3]
Sources: 59 · Level of evidence A3
Postmenopausal women
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
In postmenopausal women, the use of AIs in sequence with or as a substitute for tamoxifen has been the subject of multiple studies, the results of which have been summarized in an individual patient-level meta-analysis.[60]
Sources: 60
Initial therapy
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Evidence (AI vs. tamoxifen as initial therapy in postmenopausal women):
A large randomized trial of 9,366 patients compared the use of the AI anastrozole and the combination of anastrozole and tamoxifen with tamoxifen alone as adjuvant therapy for postmenopausal patients with lymph node–negative or lymph node–positive disease. Most (84%) of the patients in the study were hormone receptor–positive. Slightly more than 20% had received chemotherapy.[61]; [62][Level of evidence B1]
Sources: 61 · 62 · Level of evidence B1
A large randomized trial of 9,366 patients compared the use of the AI anastrozole and the combination of anastrozole and tamoxifen with tamoxifen alone as adjuvant therapy for postmenopausal patients with lymph node–negative or lymph node–positive disease. Most (84%) of the patients in the study were hormone receptor–positive. Slightly more than 20% had received chemotherapy.[61]; [62][Level of evidence B1]
With a median follow-up of 33.3 months, no benefit in DFS was observed for the combination arm relative to tamoxifen alone.[61]
Sources: 61
Patients on anastrozole, however, had a significantly longer DFS (HR, 0.83) than those on tamoxifen. In an analysis conducted after a median follow-up of 100 months among hormone receptor–positive patients, DFS was significantly (P = .003) longer in patients on anastrozole (HR, 0.85; 95% CI, 0.76–0.94), but OS was not improved (HR, 0.97; 95% CI, 0.86–1.11; P = .7).[62]
Sources: 62
Patients on tamoxifen more frequently developed endometrial cancer and cerebrovascular accidents, whereas patients on anastrozole had more fracture episodes. The frequency of myocardial infarction was similar in both groups. Except for a continued increased frequency of endometrial cancer in the tamoxifen group, these differences did not persist in the posttreatment period.[62]
Sources: 62
A large, double-blind, randomized trial of 8,010 postmenopausal women with hormone receptor–positive breast cancer compared the use of letrozole with tamoxifen given continuously for 5 years or with crossover to the alternate drug at 2 years.[63] An updated analysis from the International Breast Cancer Study Group (IBCSG-1-98 [NCT00004205]) reported results on the 4,922 women who received tamoxifen or letrozole for 5 years at a median follow-up of 51 months.[64][Level of evidence B1]
Sources: 63 · IBCSG-1-98 · 64 · Level of evidence B1
A large, double-blind, randomized trial of 8,010 postmenopausal women with hormone receptor–positive breast cancer compared the use of letrozole with tamoxifen given continuously for 5 years or with crossover to the alternate drug at 2 years.[63] An updated analysis from the International Breast Cancer Study Group (IBCSG-1-98 [NCT00004205]) reported results on the 4,922 women who received tamoxifen or letrozole for 5 years at a median follow-up of 51 months.[64][Level of evidence B1]
DFS was significantly superior in patients treated with letrozole (HR, 0.82; 95% CI, 0.71–0.95; P = .007; 5-year DFS, 84.0% vs. 81.1%).
OS was not significantly different in patients treated with letrozole (HR, 0.91; 95% CI, 0.75–1.11; P = .35).
In a meta-analysis, which included 9,885 women from multiple trials, the 10-year recurrence risk was 19.1% in the AI group versus 22.7% in the tamoxifen group (RR, 0.80; 95% CI, 0.73–0.88; P < .001). The overall 10-year mortality rate was also reduced from 24.0% to 21.3%. (RR, 0.89; 95% CI, 0.8–0.97; P = .01).[60][Level of evidence A2]
Sources: 60 · Level of evidence A2
Sequential tamoxifen and AI versus 5 years of tamoxifen
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Several trials and meta-analyses have examined the effect of switching to anastrozole or exemestane to complete a total of 5 years of therapy after 2 to 3 years of tamoxifen.[65-67] The evidence, as described below, indicates that sequential tamoxifen and AI is superior to remaining on tamoxifen for 5 years.
Evidence (sequential tamoxifen and AI vs. 5 years of tamoxifen):
Two trials carried out in sequence by the same group enrolled a total of 828 patients and were reported together; one trial used aminoglutethimide as the AI, and the other trial used anastrozole.[67]
Sources: 67
Two trials carried out in sequence by the same group enrolled a total of 828 patients and were reported together; one trial used aminoglutethimide as the AI, and the other trial used anastrozole.[67]
After a median follow-up of 78 months, an improvement in all-cause mortality (HR, 0.61; 95% CI, 0.42–0.88; P = .007) was observed in the AI groups.[67][Level of evidence A1]
Sources: 67 · Level of evidence A1
Two other trials were reported together.[66] A total of 3,224 patients were randomly assigned after 2 years of tamoxifen to continue tamoxifen for a total of 5 years or to take anastrozole for 3 years.[67]
Two other trials were reported together.[66] A total of 3,224 patients were randomly assigned after 2 years of tamoxifen to continue tamoxifen for a total of 5 years or to take anastrozole for 3 years.[67]
There was a significant difference in EFS (HR, 0.80; 95% CI; P = .0009), but not in OS (5-year OS, 97% CI for the switched arm vs. 96% CI for the tamoxifen-alone arm; P = .16).[67][Level of evidence B1]
Sources: 67 · Level of evidence B1
A large, double-blind, randomized trial (EORTC-10967 [ICCG-96OEXE031-C1396-BIG9702]) (NCT00003418) of 4,742 patients compared continuing tamoxifen with switching to exemestane for a total of 5 years of therapy in women who had received 2 to 3 years of tamoxifen.[68][Level of evidence B1]
Sources: EORTC-10967 · 68 · Level of evidence B1
A large, double-blind, randomized trial (EORTC-10967 [ICCG-96OEXE031-C1396-BIG9702]) (NCT00003418) of 4,742 patients compared continuing tamoxifen with switching to exemestane for a total of 5 years of therapy in women who had received 2 to 3 years of tamoxifen.[68][Level of evidence B1]
After the second planned interim analysis, when median follow-up for patients on the study was 30.6 months, the results were released because of a highly significant (P < .005) difference in DFS (HR, 0.68) favoring the exemestane arm.[68]
Sources: 68
After a median follow-up of 55.7 months, the HR for DFS was 0.76 (95% CI, 0.66–0.88; P = .001) in favor of exemestane.[69][Level of evidence A1]
Sources: 69 · Level of evidence A1
At 2.5 years after random assignment, 3.3% fewer patients on exemestane had developed a DFS event (95% CI, 1.6–4.9). The HR for OS was 0.85 (95% CI, 0.7–1.02; P = .08).[69]
Sources: 69
In a meta-analysis, which included 11,798 patients from six trials, the 10-year recurrence rate was reduced from 19% to 17% in the AI-containing groups (RR, 0.82; 95% CI, 0.75–0.91; P = .0001). The 10-year overall mortality rate was 17.5% in the tamoxifen group and 14.6% in the AI-containing group (RR, 0.82; 95% CI, 0.73–0.91; P = .0002).[60][Level of evidence A2]
Sources: 60 · Level of evidence A2
Sequential tamoxifen and AI for 5 years versus an AI for 5 years
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
The evidence indicates that there is no benefit to the sequential use of tamoxifen and an AI for 5 years over 5 years of an AI.
Evidence (sequential tamoxifen and AI vs. an AI for 5 years):
A large, randomized trial of 9,779 patients compared DFS of postmenopausal women with hormone receptor–positive breast cancer between initial treatment with sequential tamoxifen for 2.5 to 3 years followed by exemestane for a total of 5 years versus exemestane alone for 5 years. The primary end points were DFS at 2.75 years and 5.0 years.[70][Level of evidence B1]
Sources: 70 · Level of evidence B1
A large, randomized trial of 9,779 patients compared DFS of postmenopausal women with hormone receptor–positive breast cancer between initial treatment with sequential tamoxifen for 2.5 to 3 years followed by exemestane for a total of 5 years versus exemestane alone for 5 years. The primary end points were DFS at 2.75 years and 5.0 years.[70][Level of evidence B1]
The 5-year DFS rate was 85% in the sequential group and 86% in the exemestane-alone group (HR, 0.97; 95% CI, 0.88–1.08; P = .60).
Similarly in the IBCSG 1-98 trial (NCT00004205), two sequential arms were compared with 5 years of letrozole.[71][Level of evidence B1]
Sources: IBCSG 1-98 · 71 · Level of evidence B1
Similarly in the IBCSG 1-98 trial (NCT00004205), two sequential arms were compared with 5 years of letrozole.[71][Level of evidence B1]
There was no difference in DFS when the two sequential arms were compared with 5 years of letrozole (letrozole to tamoxifen HR, 1.06; 95% CI, 0.91–1.23; P = .45 and tamoxifen to letrozole HR, 1.07; 95% CI, 0.92–1.25; P = .36).
The FATA-GIM3 trial (NCT00541086), which was not included in the meta-analysis, compared 2 years of tamoxifen followed by 3 years of one of the three AIs with 5 years of an AI.[72]
The FATA-GIM3 trial (NCT00541086), which was not included in the meta-analysis, compared 2 years of tamoxifen followed by 3 years of one of the three AIs with 5 years of an AI.[72]
No significant difference in the 5-year DFS rate was found between the two approaches (88.5% for switching; 89.8% for upfront AI; HR, 0.89; 95% CI, 0.73–1.08; P = .23).
In a meta-analysis, which included 12,779 patients from the trials, the 7-year recurrence rate was slightly reduced from 14.5% to 13.8% in the groups that received 5 years of an AI (RR, 0.90; 95% CI, 0.81–0.99; P = .045). The overall mortality rate at 7 years was 9.3% in the tamoxifen-followed-by-AI groups and 8.2% in the AI-alone groups (RR, 0.89; 95% CI, 0.78–1.03; P = .11).[60][Level of evidence A2]
Sources: 60 · Level of evidence A2
One AI versus another for 5 years
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
The mild androgen activity of exemestane prompted a randomized trial that evaluated whether exemestane might be preferable to anastrozole, in terms of its efficacy (i.e., EFS) and toxicity, as upfront therapy for postmenopausal women diagnosed with hormone receptor–positive breast cancer.[73][Level of evidence A1] The MA27 trial (NCT00066573) randomly assigned 7,576 postmenopausal women to receive 5 years of anastrozole or exemestane.
Sources: 73 · Level of evidence A1 · MA27
The mild androgen activity of exemestane prompted a randomized trial that evaluated whether exemestane might be preferable to anastrozole, in terms of its efficacy (i.e., EFS) and toxicity, as upfront therapy for postmenopausal women diagnosed with hormone receptor–positive breast cancer.[73][Level of evidence A1] The MA27 trial (NCT00066573) randomly assigned 7,576 postmenopausal women to receive 5 years of anastrozole or exemestane.
At a median follow-up of 4.1 years, no difference in efficacy was seen (HR, 1.02; 95% CI, 0.87–1.18; P = .86).[73][Level of evidence B1]
Sources: 73 · Level of evidence B1
The two therapies also were not significantly different in terms of impact on bone mineral density or fracture rates.[74][Level of evidence B1]
Sources: 74 · Level of evidence B1
In the Femara Versus Anastrozole Clinical Evaluation (FACE) study (NCT00248170), 4,136 patients with hormone receptor–positive disease were randomly assigned to receive either letrozole or anastrozole.[75]
In the Femara Versus Anastrozole Clinical Evaluation (FACE) study (NCT00248170), 4,136 patients with hormone receptor–positive disease were randomly assigned to receive either letrozole or anastrozole.[75]
There was no significant difference in DFS (HR, 0.93; 95% CI, 0.80–1.07; P = .3150) at the time of a final analysis that was conducted when there were 709 of the planned 959 events.
There were no substantial differences in adverse events between the arms.
In the FATA-GIM3 trial, 3,697 patients with hormone receptor–positive disease were randomly assigned among the three AIs either for 5 years or after 2 years of tamoxifen.[72]
In the FATA-GIM3 trial, 3,697 patients with hormone receptor–positive disease were randomly assigned among the three AIs either for 5 years or after 2 years of tamoxifen.[72]
No significant difference in 5-year DFS (90.0% for anastrozole, 88.0% for exemestane, and 89.4% for letrozole; P = .24) was noted among the three AIs.
Switching to an AI after 5 years of tamoxifen
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
The evidence, as described below, indicates that switching to an AI after 5 years of tamoxifen is superior to stopping tamoxifen at that time.
A large, double-blinded, randomized trial (CAN-NCIC-MA17 [NCT00003140]) of 5,187 patients compared the use of letrozole versus placebo in receptor-positive postmenopausal women who received tamoxifen for approximately 5 years (range, 4.5–6.0) years.[76][Level of evidence B1]
Sources: CAN-NCIC-MA17 · 76 · Level of evidence B1
A large, double-blinded, randomized trial (CAN-NCIC-MA17 [NCT00003140]) of 5,187 patients compared the use of letrozole versus placebo in receptor-positive postmenopausal women who received tamoxifen for approximately 5 years (range, 4.5–6.0) years.[76][Level of evidence B1]
After the first planned interim analysis, when median follow-up for patients in the study was 2.4 years, the results were unblinded because of a highly significant (P < .008) difference in DFS (HR, 0.57), favoring the letrozole arm.[76]
Sources: 76
After 3 years of follow-up, 4.8% of the women on the letrozole arm had developed recurrent disease or new primaries versus 9.8% on the placebo arm (95% CI for the difference, 2.7%–7.3%). Because of the early unblinding of the study, longer-term comparative data on the risks and benefits of letrozole in this setting will not be available.[77,78]
An updated analysis including all events before unblinding confirmed the results of the interim analysis.[79] In addition, a statistically significant improvement in distant DFS was found for patients who received letrozole (HR, 0.60; 95% CI, 0.43–0.84; P = .002). Although no statistically significant difference was found in the total study population, the lymph node-positive patients who received letrozole also experienced a statistically significant improvement in OS (HR, 0.61; 95% CI, 0.38–0.98; P = .04), although the P value was not corrected for multiple comparisons.
Sources: 79
The NSABP B-33 trial (NCT00016432) that was designed to compare 5 years of exemestane with placebo after 5 years of tamoxifen was stopped prematurely when the results of CAN-NCIC-MA17 became available. At the time of analysis, 560 of the 783 patients who were randomly assigned to receive exemestane remained on that drug and 344 of the 779 patients who were randomly assigned to receive placebo had crossed over to exemestane.[80][Level of evidence B1]
Sources: NSABP B-33 · CAN-NCIC-MA17 · 80 · Level of evidence B1
The NSABP B-33 trial (NCT00016432) that was designed to compare 5 years of exemestane with placebo after 5 years of tamoxifen was stopped prematurely when the results of CAN-NCIC-MA17 became available. At the time of analysis, 560 of the 783 patients who were randomly assigned to receive exemestane remained on that drug and 344 of the 779 patients who were randomly assigned to receive placebo had crossed over to exemestane.[80][Level of evidence B1]
An intent-to-treat analysis of the primary study end point, DFS, demonstrated a nonsignificant benefit of exemestane (HR, 0.68; P = .07).
Duration of AI therapy
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
The optimal duration of AI therapy is uncertain, and multiple trials have evaluated courses longer than 5 years.
Evidence regarding extension of endocrine therapy beyond 5 years of initial AI-based adjuvant therapy:
A double-blind, randomized, phase III trial assessed the effect of an additional 5 years of letrozole versus placebo in 1,918 women who had received 5 years of an AI.[81] Patients who received previous tamoxifen therapy were included. Most women on the study (70.6%) had received 4.5 to 6 years of adjuvant tamoxifen, but a significant proportion of them (20.7%) had been treated initially with an AI. The primary study end point was DFS.
Sources: 81
A double-blind, randomized, phase III trial assessed the effect of an additional 5 years of letrozole versus placebo in 1,918 women who had received 5 years of an AI.[81] Patients who received previous tamoxifen therapy were included. Most women on the study (70.6%) had received 4.5 to 6 years of adjuvant tamoxifen, but a significant proportion of them (20.7%) had been treated initially with an AI. The primary study end point was DFS.
At a median follow-up of 6.3 years, DFS was significantly improved in patients randomly assigned to receive letrozole (HR, 0.66; 95% CI, 0.48–0.91; P = .01). The 5-year DFS rate was improved from 91% to 95%.[81][Level of evidence B1]
Sources: 81 · Level of evidence B1
OS rates showed no difference (HR, 0.97; 95% CI, 0.73–1.28; P = .83). More patients who received letrozole had fractures (14%) than did patients who received placebo (9%) (P = .001).
QOL was assessed with the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) and Menopause-Specific QOL (MENQOL) instruments. More than 85% of participants completed yearly assessments over a 5-year period.
A double-blind, randomized, phase III trial assessed the effect of an additional 5 years of letrozole versus placebo in 1,918 women who had received 5 years of an AI.[81] Patients who received previous tamoxifen therapy were included. Most women on the study (70.6%) had received 4.5 to 6 years of adjuvant tamoxifen, but a significant proportion of them (20.7%) had been treated initially with an AI. The primary study end point was DFS. › QOL was assessed with the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) and Menopause-Specific QOL (MENQOL) instruments. More than 85% of participants completed yearly assessments over a 5-year period.
No between-group differences were found on the four MENQOL subscales or on the SF-36 summary score.
SF-36 role-emotional and bodily pain scores were statistically significantly worse (P = .03) among patients receiving letrozole, but the differences observed were fewer than the minimum clinically important differences for the SF-36 instrument.
A randomized phase III study assessed the effect of an additional 2.5 years of letrozole versus 5 years of letrozole in 1,824 women who received 5 years of an AI.[Level of evidence B1] [82]
Sources: Level of evidence B1 · 82
A randomized phase III study assessed the effect of an additional 2.5 years of letrozole versus 5 years of letrozole in 1,824 women who received 5 years of an AI.[Level of evidence B1] [82]
DFS events were similar in both groups (HR, 0.92; 95% CI, 0.74–1.16). The distant metastasis-free interval was also similar (HR, 1.06; 95% CI, 0.78–1.45).
A subgroup analysis did not identify patients who benefited from 5-year extended therapy.
This study did not show that 10 years of AI therapy was superior to 7.5 years of AI therapy.
A phase III trial (NSABP-B42 [NCT00382070]) randomly assigned, in a double-blind fashion, 3,966 women who received 5 years of initial adjuvant therapy with an AI or received tamoxifen for 2 to 3 years followed by an AI to receive 5 mg of letrozole or placebo for 5 additional years.[83][Level of evidence B1] The planned analysis of DFS was carried out after a median follow-up of 6.9 years.
Sources: NSABP-B42 · 83 · Level of evidence B1
A phase III trial (NSABP-B42 [NCT00382070]) randomly assigned, in a double-blind fashion, 3,966 women who received 5 years of initial adjuvant therapy with an AI or received tamoxifen for 2 to 3 years followed by an AI to receive 5 mg of letrozole or placebo for 5 additional years.[83][Level of evidence B1] The planned analysis of DFS was carried out after a median follow-up of 6.9 years.
The 7-year DFS rate was 81.3% in the placebo group and 84.7% in the letrozole group (HR, 0.85; 95% CI, 0.73–0.999; P = .048). The observed difference was not statistically significant when interim analyses were accounted for.
There were no statistically significant differences in adverse events between the arms.
A phase III trial conducted by the IBCSG (SOLE [NCT00553410]) included 4,851 receptor-positive postmenopausal women who had completed 5 years of adjuvant therapy with an AI, a selective estrogen receptor (ER) modulator, or both. Patients were randomly assigned to receive 2.5 mg of letrozole daily for 5 years or to an intermittent schedule in which there was a 3-month break at the end of each of the first 4 years, but not in the final year.[84]
A phase III trial conducted by the IBCSG (SOLE [NCT00553410]) included 4,851 receptor-positive postmenopausal women who had completed 5 years of adjuvant therapy with an AI, a selective estrogen receptor (ER) modulator, or both. Patients were randomly assigned to receive 2.5 mg of letrozole daily for 5 years or to an intermittent schedule in which there was a 3-month break at the end of each of the first 4 years, but not in the final year.[84]
There was no observed advantage to the intermittent schedule with respect to DFS (HR, 1.08; 95% CI, 0.93–1.26; P = .31) or in the frequency of adverse events.[84][Level of evidence B1]
Sources: 84 · Level of evidence B1
A phase III trial conducted by the Dutch Breast Cancer Study Group (DATA [NCT00301457]) randomly assigned 1,860 eligible receptor-positive postmenopausal women who had received 2 to 3 years of tamoxifen to receive either 3 or 6 years of anastrozole (1 mg daily).[85]
A phase III trial conducted by the Dutch Breast Cancer Study Group (DATA [NCT00301457]) randomly assigned 1,860 eligible receptor-positive postmenopausal women who had received 2 to 3 years of tamoxifen to receive either 3 or 6 years of anastrozole (1 mg daily).[85]
At 3 years, 1,660 of these women were free of disease: among them, DFS was observed to be improved, but not statistically significantly so, on the extended-therapy arm (HR, 0.79; 95% CI, 0.62–1.02).[85][Level of evidence B1] Myalgia and osteoporosis/osteopenia were more frequent on the extended-therapy arm.
Sources: 85 · Level of evidence B1
A phase III, open-label, Italian trial (NCT01064635) included 2,056 hormone receptor–positive postmenopausal women who had received 2 to 3 years of tamoxifen treatment. Patients were randomly assigned to receive letrozole for either 2 to 3 years (control) or 5 years (extended therapy). The primary end point was IDFS.[86]
Sources: NCT01064635 · 86
A phase III, open-label, Italian trial (NCT01064635) included 2,056 hormone receptor–positive postmenopausal women who had received 2 to 3 years of tamoxifen treatment. Patients were randomly assigned to receive letrozole for either 2 to 3 years (control) or 5 years (extended therapy). The primary end point was IDFS.[86]
After 11.7 years of follow-up, the 12-year DFS rate was 62% in the control group and 67% in the extended-therapy group (HR, 0.78; 95% CI, 0.65–0.93; P = .0064). These results were confirmed in a landmark analysis that excluded patients who experienced a DFS event or who were lost to follow-up before treatment divergence (2–3 years after randomization).
The 12-year OS rate was 84% in the control group and 88% in the extended-therapy group (HR, 0.77; 95% CI, 0.60–0.98; P = .036).[86][Level of evidence A1]
Sources: 86 · Level of evidence A1
Grade 3 or greater arthralgia and myalgia were slightly more frequent in the extended-therapy group than in the control group (3.0% vs. 2.2% and 0.9% vs. 0.7%, respectively).
The phase III ABCSG-16 study enrolled 3,484 postmenopausal women with hormone receptor–positive breast cancer who had completed 5 years of endocrine therapy with tamoxifen and/or an AI to either 2 or 5 years of extended therapy with anastrozole. The primary end point was DFS in the 3,208 patients who remained in the study after 2 years. Secondary end points included OS, time to contralateral breast cancer, time to second primary cancer, fractures, and toxicity.[87]
Sources: 87
The phase III ABCSG-16 study enrolled 3,484 postmenopausal women with hormone receptor–positive breast cancer who had completed 5 years of endocrine therapy with tamoxifen and/or an AI to either 2 or 5 years of extended therapy with anastrozole. The primary end point was DFS in the 3,208 patients who remained in the study after 2 years. Secondary end points included OS, time to contralateral breast cancer, time to second primary cancer, fractures, and toxicity.[87]
After 10 years of follow-up, there was no difference in DFS between the two arms (73.6% for the 2-year course vs. 73.9% for the 5-year course [HR, 0.99; 95% CI, 0.85–1.15; P = .90]). In addition, there was no difference in OS, time to second primary cancer, and time to contralateral breast cancer between the arms.[87][Level of evidence B1]
Sources: 87 · Level of evidence B1
There was a trend toward more fractures in the 5-year arm (4.7% vs. 6.3%; HR, 1.35; 95% CI, 1.00–1.84).
An open-label trial in Japan included 1,697 patients who had received either (1) 5 years of anastrozole or (2) 2 to 3 years of tamoxifen, followed by 2 to 3 years of anastrozole. Patients were randomly assigned to either discontinue anastrozole or continue it for 5 years. The primary end point was DFS.[88]
Sources: 88
An open-label trial in Japan included 1,697 patients who had received either (1) 5 years of anastrozole or (2) 2 to 3 years of tamoxifen, followed by 2 to 3 years of anastrozole. Patients were randomly assigned to either discontinue anastrozole or continue it for 5 years. The primary end point was DFS.[88]
In an analysis done after all patients had completed protocol therapy, DFS was improved in the continued-therapy group (5-year DFS rate, 91% vs. 86%; HR, 0.62; 95% CI, 0.46–0.83; P < .0010).[88][Level of evidence B1]
Sources: 88 · Level of evidence B1
There was no difference in distant DFS or OS.
Endocrine therapy and cyclin-dependent kinase (CDK) inhibitor therapy
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
CDK4 and CDK6 have been implicated in the continued proliferation of hormone receptor–positive breast cancer that is resistant to endocrine therapy. CDK inhibitors, in combination with endocrine therapy, have been approved by the FDA in both first-line and later-line treatment of patients with advanced, HER2-negative, hormone receptor–positive breast cancer and are now being studied in the adjuvant setting. Abemaciclib is currently the only FDA-approved CDK inhibitor in the adjuvant setting.
Evidence (CDK inhibitors in the adjuvant setting):
The monarchE trial (NCT03155997) examined the effect of adding abemaciclib to standard endocrine therapy in women with HER2-negative hormone receptor–positive breast cancer who were at high risk of recurrence.[89] The trial enrolled 5,637 women who met one of the following criteria: four or more positive nodes; or one to three positive nodes and either tumor size 5 cm or larger, histological grade 3, or central Ki67 20% or greater. The women were randomly assigned in a 1:1 ratio to standard-of-care adjuvant endocrine therapy with or without open-label abemaciclib (150 mg twice daily for 2 years). The primary end point was IDFS and secondary end points included DRFS, OS, and safety.
The monarchE trial (NCT03155997) examined the effect of adding abemaciclib to standard endocrine therapy in women with HER2-negative hormone receptor–positive breast cancer who were at high risk of recurrence.[89] The trial enrolled 5,637 women who met one of the following criteria: four or more positive nodes; or one to three positive nodes and either tumor size 5 cm or larger, histological grade 3, or central Ki67 20% or greater. The women were randomly assigned in a 1:1 ratio to standard-of-care adjuvant endocrine therapy with or without open-label abemaciclib (150 mg twice daily for 2 years). The primary end point was IDFS and secondary end points included DRFS, OS, and safety.
At a median follow-up of 54 months, an analysis showed that adding abemaciclib resulted in a substantial improvement in IDFS (5-year IDFS: 76% vs. 83.6%; HR, 0.680; 95% CI, 0.599–0.772; P < .001) and DRFS (5-year DRFS: 79.2% vs. 86%; HR, 0.675; 95% CI, 0.588–0.774; P < .001).
There were 208 deaths in the abemaciclib arm and 234 deaths in the endocrine therapy-alone arm. This difference was not statistically significant.[90][Level of evidence B1]
Sources: 90 · Level of evidence B1
Because of adverse events, abemaciclib dose adjustments occurred in 1,901 patients (68.1%); 56.9% of these patients had dose omissions and 41.2% had dose reductions. In the abemaciclib arm, 463 patients (16.6%) discontinued abemaciclib because of adverse events, 306 of whom remained on endocrine therapy.[89]
Sources: 89
Similar results were found in a prespecified subgroup analysis of patients who had received neoadjuvant chemotherapy and had residual disease after surgery.[91]
Sources: 91
The NATALEE trial (NCT03701334) evaluated adding ribociclib to standard adjuvant therapy in women and men with stage II to stage III HER2-negative hormone receptor–positive breast cancer.[92] A total of 5,101 patients were randomly assigned without blinding to receive either a nonsteroidal AI alone or in combination with ribociclib within 12 months of starting a nonsteroidal AI. The primary end point was IDFS.
The NATALEE trial (NCT03701334) evaluated adding ribociclib to standard adjuvant therapy in women and men with stage II to stage III HER2-negative hormone receptor–positive breast cancer.[92] A total of 5,101 patients were randomly assigned without blinding to receive either a nonsteroidal AI alone or in combination with ribociclib within 12 months of starting a nonsteroidal AI. The primary end point was IDFS.
At the time of the second planned interim analysis, when the median duration of follow-up was 28 months, there was a significant difference in IDFS favoring the ribociclib arm (3-year IDFS, 90.4% for ribociclib plus nonsteroidal AI vs 87.1% for nonsteroidal AI alone) (HR, 0.75; 95% CI, 0.62–0.91; P = .003). This P-value exceeded the prespecified cutoff of .0256.[92][Level of evidence B1]
Sources: 92 · Level of evidence B1
The exploratory end points of distant DFS, RFS, DRFS, and OS favored the ribociclib arm, but the differences were not formally tested for significance in this analysis.
Neutropenia (62.15% vs. 4.5%) and liver-related events (25.4% vs. 10.6%) were more common in the ribociclib-plus-nonsteroidal AI group than the nonsteroidal AI-alone group. A total of 477 patients discontinued ribociclib, and 554 patients had dose reductions. There were no treatment-related deaths.
The PALLAS trial (NCT02513394) studied the effect of adding palbociclib to standard adjuvant therapy in women with stage II to stage III HER2-negative hormone receptor–positive breast cancer.[93] In the trial, 5,760 women who were within 6 months of initiating adjuvant endocrine therapy were randomly assigned in a 1:1 ratio without blinding to receive palbociclib plus endocrine therapy or to continue endocrine therapy alone. The primary end point was IDFS.
The PALLAS trial (NCT02513394) studied the effect of adding palbociclib to standard adjuvant therapy in women with stage II to stage III HER2-negative hormone receptor–positive breast cancer.[93] In the trial, 5,760 women who were within 6 months of initiating adjuvant endocrine therapy were randomly assigned in a 1:1 ratio without blinding to receive palbociclib plus endocrine therapy or to continue endocrine therapy alone. The primary end point was IDFS.
At the time of the second interim analysis, no significant difference between the treatment arms was found (HR, 0.93; 95% CI, 0.76–1.15; 3-year IDFS rates, 88.2% vs. 88.5%; P = .51).[93][Level of evidence B1] The planned final analysis yielded similar results.[94]
Sources: 93 · Level of evidence B1 · 94
As the test statistic for futility crossed the prespecified boundary, the data safety monitoring committee recommended that patients discontinue palbociclib therapy.
Neutropenia and leukopenia were much more common in patients on the palbociclib arm, and fatigue was slightly more common. There were no treatment-related deaths.
Bone-Modifying Therapy for Stages I, II, and III Breast Cancer
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Both bisphosphonates and denosumab have been evaluated as adjuvant therapies for early-stage breast cancer; however, their role is unclear. Compared with denosumab, the amount of evidence supporting bisphosphonates is greater, and there is evidence supporting a reduction in breast cancer mortality—an end point that is more clinically relevant. The optimal duration of bisphosphonate therapy is uncertain.
Evidence (bisphosphonates in the treatment of early breast cancer):
A meta-analysis included data from 18,766 patients from 26 adjuvant trials of bisphosphonates of any type.[95] Overall, reductions associated with bisphosphonate use in recurrence (RR, 0.94; 95% CI, 0.87–1.01; 2-sided P = .08), distant recurrence (RR, 0.92; 95% CI, 0.85–0.99; 2-sided P = .03), and breast cancer mortality (RR, 0.91; 95% CI, 0.83–0.99; 2-sided P = .04) were of only borderline significance, but the reduction in bone recurrence was more definite (RR, 0.83; 95% CI, 0.73–0.94; 2-sided P = .004).
Sources: 95
A meta-analysis included data from 18,766 patients from 26 adjuvant trials of bisphosphonates of any type.[95] Overall, reductions associated with bisphosphonate use in recurrence (RR, 0.94; 95% CI, 0.87–1.01; 2-sided P = .08), distant recurrence (RR, 0.92; 95% CI, 0.85–0.99; 2-sided P = .03), and breast cancer mortality (RR, 0.91; 95% CI, 0.83–0.99; 2-sided P = .04) were of only borderline significance, but the reduction in bone recurrence was more definite (RR, 0.83; 95% CI, 0.73–0.94; 2-sided P = .004).
In a prespecified subgroup analysis among premenopausal women, treatment had no apparent effect on any outcome, but among 11,767 postmenopausal women, it produced highly significant reductions in recurrence (RR, 0.86; 95% CI, 0.78–0.94; 2-sided P = .002), distant recurrence (RR, 0.82; 95% CI, 0.74–0.92; 2-sided P = .0003), bone recurrence (RR, 0.72; 95% CI, 0.60–0.86; 2-sided P = .0002), and breast cancer mortality (RR, 0.82; 95% CI, 0.73–0.93; 2-sided P = .002).[95]
Sources: 95
The ABCSG-18 trial (NCT00556374) included 3,435 postmenopausal women with receptor-positive breast cancer who were receiving an AI. Patients were randomly assigned to receive denosumab or a placebo every 6 months during AI therapy.[96] The patients were unblinded when results related to bone events were reported, and patients on placebo were allowed to cross over to the active drug.
The ABCSG-18 trial (NCT00556374) included 3,435 postmenopausal women with receptor-positive breast cancer who were receiving an AI. Patients were randomly assigned to receive denosumab or a placebo every 6 months during AI therapy.[96] The patients were unblinded when results related to bone events were reported, and patients on placebo were allowed to cross over to the active drug.
In an intent-to-treat analysis according to the original assignment, DFS, a secondary end point, was improved in patients who received denosumab (5-year DFS rate, 89.2% vs. 87.3%; HR, 0.82; 95% CI, 0.69–0.98; P = .0260).[96][Level of evidence B1]
Sources: 96 · Level of evidence B1
The frequency of adverse events was similar in the two groups.
The D-CARE trial (NCT01077154) randomly assigned 4,509 women with stage II or stage III breast cancer to receive denosumab or placebo.[97]
The D-CARE trial (NCT01077154) randomly assigned 4,509 women with stage II or stage III breast cancer to receive denosumab or placebo.[97]
The primary end point of bone metastasis–free survival was not significantly different between the groups (median, not reached in either group; HR, 0.97; 95% CI, 0.82−1.14; P = .70).[97][Level of evidence B1]
Sources: 97 · Level of evidence B1
The SUCCESS trial (NCT02181101) included 3,421 patients with node-positive or high-risk (≥pT2, grade 3, hormone receptor–negative, or aged 35 years or younger) node-negative breast cancer who completed adjuvant chemotherapy. Patients were randomly assigned to receive zoledronate 4 mg intravenously (IV) for either 2 years (every 3 months) or 5 years (every 3 months for 2 years and then every 6 months for 3 years). Only those patients who completed 2 years of zoledronate treatment (1,447 on the 2-year arm; 1,729 on the 5-year arm) were included in the final analysis. The main study end points were DFS and OS.[98]
The SUCCESS trial (NCT02181101) included 3,421 patients with node-positive or high-risk (≥pT2, grade 3, hormone receptor–negative, or aged 35 years or younger) node-negative breast cancer who completed adjuvant chemotherapy. Patients were randomly assigned to receive zoledronate 4 mg intravenously (IV) for either 2 years (every 3 months) or 5 years (every 3 months for 2 years and then every 6 months for 3 years). Only those patients who completed 2 years of zoledronate treatment (1,447 on the 2-year arm; 1,729 on the 5-year arm) were included in the final analysis. The main study end points were DFS and OS.[98]
Outcomes were similar between the two arms for DFS (HR, 0.97; 95% CI, 0.76–1.25; P = .83) and OS (HR, 0.93; 95% CI, 0.65–1.34; P = .71).[98][Level of evidence A1]
Sources: 98 · Level of evidence A1
An accompanying editorial explained why the results of this study do not definitively establish how long bisphosphonates should be administered.[99]
Sources: 99
Adjuvant PARP Inhibitors for Patients with Germline BRCA1 and BRCA2 Variants
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
The role of adjuvant poly (ADP-ribose) polymerase (PARP) inhibition has been evaluated in patients with early-onset breast cancer and germline BRCA1 or BRCA2 pathogenic variants. BRCA1 and BRCA2 are tumor suppressor genes that encode proteins involved in DNA repair (via the homologous recombination repair pathway). PARP plays a critical role in DNA repair.
Evidence (olaparib):
The OlympiA trial (NCT02032823) randomly assigned 1,836 patients with HER2-negative breast cancer and germline BRCA1 or BRCA2 pathogenic variants to receive either 1 year of adjuvant olaparib (300 mg twice daily) or placebo. All women completed surgery and adjuvant or neoadjuvant chemotherapy or radiation therapy. Patients were considered at higher risk of recurrence on the basis of tumor size, node involvement, or the presence of residual cancer after neoadjuvant therapy.[100]Eligibility criteria for patients who underwent initial surgery and received adjuvant chemotherapy Eligibility criteria for patients who underwent neoadjuvant chemotherapy followed by surgeryThe primary study end point was invasive disease-free survival (IDFS).[100][Level of evidence B1]
Sources: OlympiA · 100 · 100 · Level of evidence B1
The OlympiA trial (NCT02032823) randomly assigned 1,836 patients with HER2-negative breast cancer and germline BRCA1 or BRCA2 pathogenic variants to receive either 1 year of adjuvant olaparib (300 mg twice daily) or placebo. All women completed surgery and adjuvant or neoadjuvant chemotherapy or radiation therapy. Patients were considered at higher risk of recurrence on the basis of tumor size, node involvement, or the presence of residual cancer after neoadjuvant therapy.[100]Eligibility criteria for patients who underwent initial surgery and received adjuvant chemotherapy Eligibility criteria for patients who underwent neoadjuvant chemotherapy followed by surgeryThe primary study end point was invasive disease-free survival (IDFS).[100][Level of evidence B1]
Patients with triple-negative breast cancer (TNBC) had axillary node-positive (≥pN1, any tumor size) disease OR axillary node-negative disease with an invasive primary tumor larger than 2 cm (pN0, ≥pT2).
At least four pathologically confirmed positive lymph nodes were required for ER- and/or PR-positive/HER2-negative patients.
Patients with TNBC had residual invasive cancer in the breast and/or resected lymph nodes (i.e., no pCR).
ER- and/or PR-positive/HER2-negative patients had residual invasive cancer in the breast and/or resected lymph nodes (i.e., no pCR) AND a CPS+EG (Clinical stage/Pathological Stage + ER status/nuclear Grade) score of 3 or higher.[101]
Sources: 101
At the time of the first (and only) planned interim analysis, when 284 events (i.e., invasive disease or death) had occurred, the HR for IDFS strongly favored the olaparib arm, and the prespecified stopping boundary for significance was exceeded (3-year IDFS rate, 85.9% vs 77.1%; HR, 0.58; 99.5% CI, 0.41–0.82; P < .001).[100][Level of evidence B1]
Sources: 100 · Level of evidence B1
Distant DFS was also statistically significantly improved for patients who received olaparib (HR, 0.57; 99.5% CI, 0.39–0.83; P < .001).
A difference in OS was also observed (HR, 0.68; 99% CI, 0.44–1.05; P = .02), but it did not meet the prespecified level of significance when corrected for multiple testing (P < .01).
Grade 3 or higher adverse events that occurred in more than 1% of patients on the olaparib arm included anemia (8.7%), decreased neutrophil count (4.8%), decreased white cell count (3.0%), fatigue (1.8%), and lymphopenia (1.2%). No adverse events of grade 3 or higher occurred in more than 1% of the patients on the placebo arm.
Patient-reported outcomes were assessed among the 1,538 patients who completed both a baseline questionnaire and at least one subsequent questionnaire.[102]
Sources: 102
The OlympiA trial (NCT02032823) randomly assigned 1,836 patients with HER2-negative breast cancer and germline BRCA1 or BRCA2 pathogenic variants to receive either 1 year of adjuvant olaparib (300 mg twice daily) or placebo. All women completed surgery and adjuvant or neoadjuvant chemotherapy or radiation therapy. Patients were considered at higher risk of recurrence on the basis of tumor size, node involvement, or the presence of residual cancer after neoadjuvant therapy.[100]Eligibility criteria for patients who underwent initial surgery and received adjuvant chemotherapy Eligibility criteria for patients who underwent neoadjuvant chemotherapy followed by surgeryThe primary study end point was invasive disease-free survival (IDFS).[100][Level of evidence B1] › Patient-reported outcomes were assessed among the 1,538 patients who completed both a baseline questionnaire and at least one subsequent questionnaire.[102]
Patients who received olaparib experienced statistically significant greater fatigue than patients who received placebo, but the differences did not meet the criteria for clinical significance. The fatigue resolved over time after cessation of therapy.
Patients who received olaparib had small but statistically and clinically significant increases in nausea, vomiting, and appetite loss scores during treatment.[102][Level of evidence A3]
Sources: 102 · Level of evidence A3
Stages I, II, and III Triple-Negative Breast Cancer (TNBC)
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
TNBC is defined as the absence of staining for ER, PR, and HER2. TNBC is insensitive to some of the most effective therapies for patients with breast cancer, including HER2-directed therapy such as trastuzumab and endocrine therapies such as tamoxifen or AIs.
Preoperative therapy for TNBC
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Patients with TNBC are frequently treated with preoperative systemic therapy.
Chemotherapy
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Promising results have been observed with the addition of carboplatin to anthracycline/taxane combination chemotherapy regimens in patients with TNBC.
Evidence (adding carboplatin to an anthracycline/taxane–based chemotherapy regimen in patients with TNBC):
In the GeparSixto trial (NCT01426880), carboplatin was added to an anthracycline/taxane–based backbone.[103][Level of evidence B3]
Sources: GeparSixto · 103 · Level of evidence B3
In the GeparSixto trial (NCT01426880), carboplatin was added to an anthracycline/taxane–based backbone.[103][Level of evidence B3]
Higher pCR rates were observed with the addition of carboplatin to an anthracycline/taxane–based backbone compared with anthracycline/taxane alone (36.9% vs. 53.2%; P = .005) in patients with TNBC.
Patients with BRCA1 or BRCA2 variants had a higher rate of pCR, which was not increased by the addition of carboplatin (66.7% in the nonplatinum arm vs. 65.7% in the platinum-containing arm).
The 3-year DFS rate was higher for patients with TNBC randomly assigned to the carboplatin arm (86.1% vs. 75.8%; HR, 0.56; 95% CI, 0.34−0.93), but OS did not differ.[104]
Sources: 104
The more intensive regimen was also associated with increased toxicity and treatment discontinuations (39% vs. 48%).
The CALGB 40603 trial (NCT00861705) compared an anthracycline/taxane backbone alone with an anthracycline/taxane backbone plus carboplatin in patients with stage II and stage III TNBC.[105][Level of evidence B3]
Sources: CALGB 40603 · 105 · Level of evidence B3
The CALGB 40603 trial (NCT00861705) compared an anthracycline/taxane backbone alone with an anthracycline/taxane backbone plus carboplatin in patients with stage II and stage III TNBC.[105][Level of evidence B3]
The pCR rate for the breast and axilla was 54% for the anthracycline/taxane backbone-plus-carboplatin group versus 41% for the anthracycline/taxane backbone-alone group (P = .0029).
Immunotherapy
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Evidence (adding pembrolizumab to a chemotherapy regimen in patients with stage II or stage III TNBC):
The randomized, double blind, phase III KEYNOTE-522 trial (NCT03036488) evaluated the addition of immunotherapy to neoadjuvant chemotherapy for patients with stage II and stage III TNBC.[106][Level of evidence B1] Participants were randomly assigned in a 2:1 ratio to receive neoadjuvant chemotherapy (paclitaxel plus carboplatin, followed by doxorubicin plus cyclophosphamide) with either neoadjuvant and adjuvant pembrolizumab or neoadjuvant and adjuvant placebo. Co-primary end points were pCR rate and EFS. The pCR rate, as reported at the time of the first interim analysis for the first 602 participants (pembrolizumab arm, n = 401; placebo arm, n = 201), favored the pembrolizumab arm.
Sources: KEYNOTE-522 · 106 · Level of evidence B1
The randomized, double blind, phase III KEYNOTE-522 trial (NCT03036488) evaluated the addition of immunotherapy to neoadjuvant chemotherapy for patients with stage II and stage III TNBC.[106][Level of evidence B1] Participants were randomly assigned in a 2:1 ratio to receive neoadjuvant chemotherapy (paclitaxel plus carboplatin, followed by doxorubicin plus cyclophosphamide) with either neoadjuvant and adjuvant pembrolizumab or neoadjuvant and adjuvant placebo. Co-primary end points were pCR rate and EFS. The pCR rate, as reported at the time of the first interim analysis for the first 602 participants (pembrolizumab arm, n = 401; placebo arm, n = 201), favored the pembrolizumab arm.
A pCR was observed in 64.8% of patients in the pembrolizumab arm and 51.2% of patients in the placebo arm (estimated treatment difference, 13.6%; 95% CI, 5.4%−21.8%; P < .001). Approximately 80% of tumors were positive for programmed death-ligand 1 (PD-L1), but the benefits of pembrolizumab regarding pCR were observed regardless of PD-L1 status.
At the time of the fourth interim analysis, when the median follow-up was 39 months, an improved EFS was observed in patients who received pembrolizumab. The 36-month EFS rate was 84.5% for patients who received pembrolizumab and 76.8% for patients who received placebo. (HR, 0.63; 95% CI, 0.48–0.82; P < .001).[107][Level of evidence B1]
Sources: 107 · Level of evidence B1
EFS data are immature.
Grade 3 or higher adverse events occurred in 76.8% of participants in the pembrolizumab arm and 72.2% of participants in the placebo arm. Serious treatment-related adverse events occurred in 32.5% of participants in the pembrolizumab arm and 19.5% of participants in the placebo arm. Grade 3 or higher skin rashes, infusion reactions, and adrenal insufficiency were more frequent in the pembrolizumab arm.
Postoperative therapy for TNBC
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
For patients who undergo surgery first, combination chemotherapy is typically given in the adjuvant setting. While there is no established standard therapy in this setting, the following trial provides evidence that a non–anthracycline-based regimen may be suitable:
Evidence (adjuvant non–anthracycline-containing regimens):
The PATTERN trial (NCT01216111) compared an anthracycline-based regimen (cyclophosphamide, 5-FU, epirubicin, and docetaxel [CEF-T]) with paclitaxel and carboplatin (PCb) in 647 Chinese women with TNBC who had completed definitive surgery. The primary end point was DFS.[108]
The PATTERN trial (NCT01216111) compared an anthracycline-based regimen (cyclophosphamide, 5-FU, epirubicin, and docetaxel [CEF-T]) with paclitaxel and carboplatin (PCb) in 647 Chinese women with TNBC who had completed definitive surgery. The primary end point was DFS.[108]
At a median follow-up of 62 months, the 5-year DFS rate was 86.5% for patients who received PCb and 80.3% for patients who received CEF-T (HR, 0.65; 95% CI, 0.44–0.96; P = .03).[108][Level of evidence B1]
Sources: 108 · Level of evidence B1
There was no statistically significant difference in OS between the groups (HR, 0.71; 95% CI, 0.42–1.22; P = .22).
Capecitabine therapy
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Capecitabine therapy increased DFS when given after conventional adjuvant therapy.
Evidence (capecitabine therapy for patients who have not been treated with preoperative systemic therapy):
The SYSUCC-001 trial (NCT01112826) included 443 women (434 analyzed) with TNBC from 13 Chinese institutions. The women had received adjuvant chemotherapy and were randomly assigned to receive either no further therapy or capecitabine at a dose of 650 mg/m2 twice daily for 1 year. The primary study end point was DFS.[109]
Sources: SYSUCC-001 · 109
The SYSUCC-001 trial (NCT01112826) included 443 women (434 analyzed) with TNBC from 13 Chinese institutions. The women had received adjuvant chemotherapy and were randomly assigned to receive either no further therapy or capecitabine at a dose of 650 mg/m2 twice daily for 1 year. The primary study end point was DFS.[109]
After a median follow-up of 61 months, the 5-year DFS rate was 82.5% for patients who received capecitabine maintenance therapy compared with 73.0% for patients who received no further therapy (HR, 0.64; 95% CI, 0.42–0.95; P = .03).[109][Level of evidence B1]
Sources: 109 · Level of evidence B1
Forty-five percent of patients who received capecitabine developed hand-foot syndrome, which was grade 3 in 7.7% of patients.
The rate of patients who completed 1 year of therapy was 82.8%.
Evidence (capecitabine therapy for patients who have been treated with preoperative systemic therapy):
In a study conducted in Japan and Korea, 910 women with HER2-negative breast cancers were randomly assigned in a nonblinded fashion to receive six to eight 3-week cycles of capecitabine or no further chemotherapy. Patients had residual disease after preoperative chemotherapy with anthracyclines, taxanes, or both, and 30% of the patients also had hormone receptor–negative disease. The primary end point was DFS.[110] The study was terminated because of the results of a planned interim analysis, and a final analysis was done.
Sources: 110
In a study conducted in Japan and Korea, 910 women with HER2-negative breast cancers were randomly assigned in a nonblinded fashion to receive six to eight 3-week cycles of capecitabine or no further chemotherapy. Patients had residual disease after preoperative chemotherapy with anthracyclines, taxanes, or both, and 30% of the patients also had hormone receptor–negative disease. The primary end point was DFS.[110] The study was terminated because of the results of a planned interim analysis, and a final analysis was done.
In the final analysis, which included 887 eligible patients the 5-year DFS rate was 74.1% in the capecitabine group and 67.6% in the no-further-chemotherapy group (HR, 0.70; 95% CI, 0.53–0.92; P = .01).[Level of evidence B1]
Sources: Level of evidence B1
OS was a secondary end point. The 5-year OS rate was 89.2% in the capecitabine group and 83.6% in the no-further-chemotherapy group (HR, 0.59; 95% CI, 0.39–0.90; P = .01).
In a subset analysis, OS was significantly prolonged only in the patients with hormone receptor–negative disease. Among those patients, the 5-year OS rate was 78.8% in the capecitabine group and 70.3% in the no-further-chemotherapy group (HR, 0.52; 95% CI, 0.30–0.90).
In the capecitabine group, 73.4% of the patients experienced hand-foot syndrome of varying degrees of severity.
These approaches should be considered for patients with residual disease after preoperative therapy. Patients may also consider participation in clinical trials of novel therapies. Clinical trials for this patient population have included EA1131 (NCT02445391), a phase III clinical trial that randomly assigned patients with residual basal-like TNBC after preoperative therapy to receive either platinum-based chemotherapy or capecitabine, and S1418/BR006 (NCT02954874), a phase III trial that evaluated the efficacy of pembrolizumab as adjuvant therapy for patients with residual TNBC (≥1 cm invasive cancer or residual nodes) after preoperative therapy. Information about ongoing clinical trials is available from the NCI website.
Sources: EA1131 · S1418/BR006 · NCI website
Immunotherapy
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
One completed trial showed no benefit to adding atezolizumab to postoperative chemotherapy.
Evidence (postoperative atezolizumab):
In the ALEXANDRA/IMpassion030 trial (NCT03498716), 2,199 women who had not received preoperative systemic therapy were randomly assigned postoperatively to receive chemotherapy with or without atezolizumab. The chemotherapy regimen included paclitaxel and cyclophosphamide with doxorubicin or epirubicin. The primary end point was IDFS. Trial accrual was prematurely terminated by the data safety monitoring committee for futility.[111]
Sources: ALEXANDRA/IMpassion030 · 111
In the ALEXANDRA/IMpassion030 trial (NCT03498716), 2,199 women who had not received preoperative systemic therapy were randomly assigned postoperatively to receive chemotherapy with or without atezolizumab. The chemotherapy regimen included paclitaxel and cyclophosphamide with doxorubicin or epirubicin. The primary end point was IDFS. Trial accrual was prematurely terminated by the data safety monitoring committee for futility.[111]
The final analysis demonstrated no benefit in IDFS with the addition of atezolizumab (HR, 1.11; 95% CI, 0.87–1.42; P = .38).[111][Level of evidence B1]
Sources: 111 · Level of evidence B1
Stages I, II, and III HER2-Positive Breast Cancer
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Patients with HER2-positive breast cancer who are also hormone receptor–positive receive hormone therapy as described in the Stages I, II, and III HER2-Negative Hormone Receptor–Positive Breast Cancer section.
Sources: Stages I, II, and III HER2-Negative Hormone Receptor–Positive Breast Cancer
Preoperative therapy for HER2-positive breast cancer
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
After the success in the adjuvant setting, initial reports from phase II studies indicated improved pCR rates when trastuzumab, a monoclonal antibody that binds the extracellular domain of HER2, was added to preoperative anthracycline/taxane–based regimens.[112][Level of evidence B3] This has been confirmed in phase III studies.[113,114]
Sources: 112 · Level of evidence B3 · 113 · 114
Trastuzumab
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Evidence (trastuzumab):
The phase III NeOAdjuvant Herceptin (NOAH) study randomly assigned patients with HER2-positive locally advanced or inflammatory breast cancers to undergo preoperative chemotherapy with or without 1 year of trastuzumab therapy.[114][Level of evidence A1]
Sources: 114 · Level of evidence A1
The phase III NeOAdjuvant Herceptin (NOAH) study randomly assigned patients with HER2-positive locally advanced or inflammatory breast cancers to undergo preoperative chemotherapy with or without 1 year of trastuzumab therapy.[114][Level of evidence A1]
Study results confirmed that the addition of trastuzumab to preoperative chemotherapy resulted not only in improved clinical responses (87% vs. 74%) and pathological responses (breast and axilla, 38% vs. 19%) but also in EFS, the primary outcome.[114][Level of evidence A1]
Sources: 114 · Level of evidence A1
After a median follow-up of 5.4 years, the EFS benefit was 58% with the addition of trastuzumab to chemotherapy (95% CI, 48%–66%) and 43% (95% CI, 34%–52%) in patients in the chemotherapy group. The unadjusted HR for EFS between the two randomized HER2-positive treatment groups was 0.64 (95% CI, 0.44–0.93; two-sided log-rank P = .016). EFS was strongly associated with pCR in patients who received trastuzumab.[115]
Sources: 115
Symptomatic cardiac failure occurred in two patients who received concurrent doxorubicin and trastuzumab for two cycles. Close cardiac monitoring of left ventricular ejection fraction (LVEF) and the total dose of doxorubicin not exceeding 180 mg/m2 accounted for the relatively low number of declines in LVEF and only two cardiac events. For more information, see the Cardiac Toxic Effects With Adjuvant Trastuzumab section.[114][Level of evidence B1]
Sources: Cardiac Toxic Effects With Adjuvant Trastuzumab · 114 · Level of evidence B1
Due to concern about coadministration of trastuzumab and anthracyclines, a phase III trial (Z1041 [NCT00513292]) randomly assigned patients with operable HER2-positive breast cancer to receive trastuzumab sequential to or concurrent with the anthracycline component (5-FU, epirubicin, and cyclophosphamide [FEC]) of the preoperative chemotherapy regimen.[116][Level of evidence B3]
Sources: Z1041 · 116 · Level of evidence B3
Due to concern about coadministration of trastuzumab and anthracyclines, a phase III trial (Z1041 [NCT00513292]) randomly assigned patients with operable HER2-positive breast cancer to receive trastuzumab sequential to or concurrent with the anthracycline component (5-FU, epirubicin, and cyclophosphamide [FEC]) of the preoperative chemotherapy regimen.[116][Level of evidence B3]
The primary outcome was pCR. There was no significant difference in pCR rate in the breast between the arms (56.5% sequential, 54.2% concurrent; difference, 2.3%; 95% CI, -9.3 to 13.9).
Asymptomatic declines in LVEF during preoperative chemotherapy were identified in similar proportions of patients in each arm.
DFS and OS were secondary outcomes. After median follow-up of 5.1 years, there was no difference in DFS (HR, 1.02; 95% CI, 0.56−1.83; P = .96) or OS (HR, 1.17; 95% CI, 0.48−2.88; P = .73) between the sequential and concurrent arms.[117]
Sources: 117
Based on these findings, concurrent administration of trastuzumab with anthracyclines is not warranted.
A subcutaneous (SQ) formulation of trastuzumab has also been approved.
The SafeHer trial (NCT01566721) evaluated the safety and tolerability of self-administered versus clinician-administered SQ trastuzumab in patients with stage I to stage III HER2-positive breast cancer.[118] Chemotherapy was administered concurrently or sequentially.
A phase III (HannaH [NCT00950300]) trial also demonstrated that the pharmacokinetics and efficacy of preoperative SQ trastuzumab is noninferior to the IV formulation. This international open-label trial (n = 596) randomly assigned women with operable, locally advanced, or inflammatory HER2-positive breast cancer to undergo preoperative chemotherapy (anthracycline/taxane–based), with either SQ-administered or IV-administered trastuzumab every 3 weeks before surgery. Patients received adjuvant trastuzumab to complete 1 year of therapy.[119][Level of evidence B1] The pCR rates between the arms differed by 4.7% (95% CI, 4.0%–13.4%); 40.7% in the IV-administered group versus 45.4% in the SQ-administered group, demonstrating noninferiority for the SQ formulation. EFS and OS were secondary end points. The 6-year EFS rate was 65% in both arms (HR, 0.98; 95% CI, 0.74−1.29). The 6-year OS rate was 84% in both arms (HR, 0.94; 95% CI, 0.61−1.45).[120]
Sources: HannaH · 119 · Level of evidence B1 · 120
Pertuzumab
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Pertuzumab is a humanized monoclonal antibody that binds to a distinct epitope on the extracellular domain of the HER2 receptor and inhibits dimerization. Pertuzumab, in combination with trastuzumab with or without chemotherapy, has been evaluated in two preoperative clinical trials to improve on the pCR rates observed with trastuzumab and chemotherapy.
Evidence (pertuzumab):
In the open-label, randomized, phase II NeoSPHERE trial (NCT00545688),[121] 417 women with tumors that were larger than 2 cm or node-positive, and who had HER2-positive breast cancer, were randomly assigned to one of four preoperative regimens:[121][Level of evidence B3]The following results were observed:
Sources: NeoSPHERE · 121 · 121 · Level of evidence B3
In the open-label, randomized, phase II NeoSPHERE trial (NCT00545688),[121] 417 women with tumors that were larger than 2 cm or node-positive, and who had HER2-positive breast cancer, were randomly assigned to one of four preoperative regimens:[121][Level of evidence B3]The following results were observed:
Docetaxel plus trastuzumab.
Docetaxel plus trastuzumab and pertuzumab.
Pertuzumab plus trastuzumab.
Docetaxel plus pertuzumab.
The pCR rates were 29% for docetaxel plus trastuzumab, 46% for docetaxel plus trastuzumab and pertuzumab, 17% for pertuzumab plus trastuzumab, and 24% for docetaxel plus pertuzumab. Therefore, the highest pCR rate was seen in the preoperative treatment arm with dual HER2 blockade plus chemotherapy.
The addition of pertuzumab to the docetaxel-plus-trastuzumab combination did not appear to increase toxic effects, including the risk of cardiac adverse events.
Despite the high pCR rate observed with dual HER2 blockade plus chemotherapy, PFS and DFS rates were not improved, although the NeoSPHERE trial was not powered to detect differences in long-term efficacy outcomes.[123]
Sources: 123
The open-label, randomized, phase II TRYPHAENA trial (NCT00976989) sought to evaluate the tolerability and activity associated with trastuzumab and pertuzumab.[124][Level of evidence B3] All 225 women with tumors that were larger than 2 cm or node positive, and who had operable, locally advanced, or inflammatory HER2-positive breast cancer, were randomly assigned to one of three preoperative regimens: The following results were observed:
Sources: TRYPHAENA · 124 · Level of evidence B3
The open-label, randomized, phase II TRYPHAENA trial (NCT00976989) sought to evaluate the tolerability and activity associated with trastuzumab and pertuzumab.[124][Level of evidence B3] All 225 women with tumors that were larger than 2 cm or node positive, and who had operable, locally advanced, or inflammatory HER2-positive breast cancer, were randomly assigned to one of three preoperative regimens: The following results were observed:
Concurrent FEC plus trastuzumab plus pertuzumab (×3) followed by concurrent docetaxel plus trastuzumab plus pertuzumab.
FEC alone (×3) followed by concurrent docetaxel plus trastuzumab plus pertuzumab (×3).
Concurrent docetaxel and carboplatin plus trastuzumab plus pertuzumab (×6).
The pCR rate was equivalent across all three treatment arms: (62% for concurrent FEC plus trastuzumab plus pertuzumab followed by concurrent docetaxel plus trastuzumab plus pertuzumab; 57% for FEC alone followed by concurrent docetaxel plus trastuzumab plus pertuzumab; and 66% for concurrent docetaxel and carboplatin plus trastuzumab plus pertuzumab).
All three arms were associated with a low incidence of cardiac adverse events of 5% or less.
Because of these studies, the FDA granted accelerated approval of pertuzumab as part of a preoperative treatment for women with early-stage, HER2-positive breast cancer whose tumors are larger than 2 cm or node-positive.
The FDA approval of pertuzumab was subsequently converted to regular approval following the results of the confirmatory APHINITY trial (NCT01358877), a randomized, phase III, adjuvant study for women with HER2-positive breast cancer. Study results demonstrated improved IDFS with the combination of chemotherapy and dual HER2-targeted therapy with pertuzumab plus trastuzumab compared with chemotherapy and trastuzumab alone.[125] Pertuzumab is now approved both in combination with trastuzumab and chemotherapy for the neoadjuvant therapy of locally advanced, inflammatory, or early-stage HER2-positive breast cancer, which is larger than 2 cm or node-positive, as part of a complete treatment regimen and in combination with chemotherapy and trastuzumab as adjuvant treatment for HER2-positive early breast cancer at a high risk of recurrence.
The randomized, open-label, multicenter TRAIN-2 trial (NCT01996267) evaluated the optimal chemotherapy backbone to use with neoadjuvant pertuzumab and trastuzumab in patients with stage II to stage III HER2-positive breast cancer (i.e., an anthracycline-containing or non–anthracycline-containing regimen).[126,127][Level of evidence B3] A total of 438 patients were randomly assigned to receive one of the following regimens:
Sources: TRAIN-2 · 126 · 127 · Level of evidence B3
FEC every 3 weeks for three cycles followed by paclitaxel and carboplatin every 3 weeks for six cycles. Paclitaxel was administered on days 1 and 8 and carboplatin was administered either on day 1 alone or on days 1 and 8. Trastuzumab and pertuzumab were given every 3 weeks throughout chemotherapy. Primary prophylaxis with filgrastim was not administered during the FEC portion of therapy.
Paclitaxel and carboplatin according to the same schedule for nine cycles. Trastuzumab and pertuzumab were given every 3 weeks throughout chemotherapy.
The primary end point was pCR (ypT0/is, ypN0). Secondary end point data on EFS, OS, toxicity, and breast conservation are available. The following results were observed:
There was no statistically significant difference in the proportion of patients with pCR between the anthracycline (67%) and non-anthracycline (68%) arm.
There was no difference in the proportion of patients in each arm who underwent breast-conserving surgery.
Irrespective of hormone receptor and nodal status, 3-year EFS estimates were 92.7% in the anthracycline group and 93.6% in the non-anthracycline group. The 3-year OS estimates were 97.7% in the anthracycline group and 98.2% in the non-anthracycline group.
A decline in LVEF of 10% or more from baseline to less than 50% was more common in patients who received anthracyclines than those who did not (7.7% vs. 3.2%; P = .04).
Two patients treated with anthracyclines developed acute leukemia.
There was no difference in the proportion of patients in each arm with at least grade 2 peripheral neuropathy: 66 patients (30%) in the anthracycline arm versus 68 patients (31%) in the non-anthracycline arm.
Grade 4 neutropenia and febrile neutropenia were more common in the anthracycline arm (23 patients [10%]) than in the non-anthracycline arm (3 patients [1%], P < .0001).
Postoperative therapy for HER2-positive breast cancer
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Patients who have not been treated with preoperative systemic therapy.
Standard treatment for HER2-positive early breast cancer is 1 year of adjuvant HER2-targeted therapy.
Trastuzumab
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Several phase III clinical trials have addressed the role of the anti-HER2 antibody, trastuzumab, as adjuvant therapy for patients with HER2-overexpressing cancers. Study results confirm the benefit of 1 year of adjuvant trastuzumab therapy.
Evidence (including duration of trastuzumab therapy for patients who have not been treated with preoperative systemic therapy):
The Herceptin Adjuvant (HERA) (BIG-01-01 [NCT00045032]) trial examined the efficacy of trastuzumab as adjuvant treatment for HER2-positive breast cancer if used after completion of the primary treatment. For most patients, primary treatment consisted of an anthracycline-containing chemotherapy regimen given preoperatively or postoperatively, with or without locoregional radiation therapy. Trastuzumab was given every 3 weeks starting within 7 weeks of the completion of primary treatment.[128][Level of evidence A1] Patients were randomly assigned to one of three study arms:Of the patients in the group comparing 1 year of trastuzumab versus observation, the median age was 49 years, about 33% had node-negative disease, and nearly 50% had hormone receptor–negative disease.[129]The following results were observed for patients assigned to 1 year of trastuzumab versus patients assigned to observation:The following results were observed for patients assigned to 1 year of trastuzumab versus patients assigned to 2 years of trastuzumab:Symptomatic cardiac events occurred in 1% of the patients who received trastuzumab and in 0.1% of the observation group.
Sources: BIG-01-01 · 128 · Level of evidence A1 · 129
The Herceptin Adjuvant (HERA) (BIG-01-01 [NCT00045032]) trial examined the efficacy of trastuzumab as adjuvant treatment for HER2-positive breast cancer if used after completion of the primary treatment. For most patients, primary treatment consisted of an anthracycline-containing chemotherapy regimen given preoperatively or postoperatively, with or without locoregional radiation therapy. Trastuzumab was given every 3 weeks starting within 7 weeks of the completion of primary treatment.[128][Level of evidence A1] Patients were randomly assigned to one of three study arms:Of the patients in the group comparing 1 year of trastuzumab versus observation, the median age was 49 years, about 33% had node-negative disease, and nearly 50% had hormone receptor–negative disease.[129]The following results were observed for patients assigned to 1 year of trastuzumab versus patients assigned to observation:The following results were observed for patients assigned to 1 year of trastuzumab versus patients assigned to 2 years of trastuzumab:Symptomatic cardiac events occurred in 1% of the patients who received trastuzumab and in 0.1% of the observation group.
Observation (n = 1,693).
1 year of trastuzumab (n = 1,694).
2 years of trastuzumab (n = 1,694).
After a median follow-up of 11 years,[129] 1 year of trastuzumab improved DFS (10-year DFS rate, 72% vs. 66%; HR, 0.76; 95% CI, 0.68–0.86; P < .0001), despite a crossover of 52% of the patients on observation.
Sources: 129
One year of trastuzumab also improved OS (12-year OS rate, 79% vs. 73%; HR, 0.74; 95% CI, 0.64–0.86; P < .0001).[129][Level of evidence A1]
Sources: 129 · Level of evidence A1
After a median follow-up of 11 years, there was no DFS benefit to an additional year of trastuzumab (HR, 1.02; 95% CI, 0.89–1.17).
In the combined analysis of the NSABP-B-31 (NCT00004067) and intergroup NCCTG-N9831 (NCT00005970) trials, trastuzumab was given weekly, concurrently, or immediately after the paclitaxel component of the AC with paclitaxel regimen.[130,131][Level of evidence A1]
Sources: NSABP-B-31 · NCCTG-N9831 · 130 · 131 · Level of evidence A1
In the combined analysis of the NSABP-B-31 (NCT00004067) and intergroup NCCTG-N9831 (NCT00005970) trials, trastuzumab was given weekly, concurrently, or immediately after the paclitaxel component of the AC with paclitaxel regimen.[130,131][Level of evidence A1]
The HERA results were confirmed in a joint analysis of the two studies, with a combined enrollment of 3,676 patients. A highly statistically significant improvement in DFS (3-year DFS rate, 87% vs. 75%; HR, 0.48; P < .001) was observed, as was a significant improvement in OS (3-year OS rate, 94.3% in the trastuzumab group vs. 91.7% in the control group; 4-year OS rate, 91.4% in the trastuzumab group vs. 86.6% in the control group; HR, 0.67; P = .015).[130]
Sources: 130
Patients treated with trastuzumab experienced a longer DFS, with a 52% lower risk of a DFS event (HR, 0.48; 95% CI, 0.39–0.59; P < .001), corresponding to an absolute difference in DFS of 11.8% at 3 years and 18% at 4 years. The risk of distant recurrence in patients treated with trastuzumab was 53% lower (HR, 0.47; 95% CI, 0.37–0.61; P < .001), and the risk of death was 33% lower (HR, 0.67; 95% CI, 0.48–0.93; P = .015).[130]
Sources: 130
In an updated analysis with a median follow-up of 8.4 years, the addition of trastuzumab to chemotherapy led to a 37% relative improvement in OS (HR, 0.63; 95% CI, 0.54–0.73; P < .001) and an increase in the 10-year OS rate from 75.2% to 84%.[132]
Sources: 132
In the BCIRG-006 trial (NCT00021255), 3,222 women with early-stage HER2-overexpressing breast cancer were randomly assigned to receive AC followed by docetaxel (AC-T), AC followed by docetaxel plus trastuzumab (AC-T plus trastuzumab), or docetaxel, carboplatin, plus trastuzumab (TCH, a non–anthracycline-containing regimen).[133][Level of evidence A1]
Sources: BCIRG-006 · 133 · Level of evidence A1
In the BCIRG-006 trial (NCT00021255), 3,222 women with early-stage HER2-overexpressing breast cancer were randomly assigned to receive AC followed by docetaxel (AC-T), AC followed by docetaxel plus trastuzumab (AC-T plus trastuzumab), or docetaxel, carboplatin, plus trastuzumab (TCH, a non–anthracycline-containing regimen).[133][Level of evidence A1]
A significant DFS and OS benefit was seen in both groups treated with trastuzumab compared with the control group that did not receive trastuzumab.
For patients receiving AC-T plus trastuzumab, the 5-year DFS rate was 84% (HR for the comparison with AC-T, 0.64; P < .001), and the OS rate was 92% (HR, 0.63; P < .001). For patients receiving TCH, the 5-year DFS rate was 81% (HR, 0.75; P = .04), and the OS rate was 91% (HR, 0.77; P = .04). The control group had a 5-year DFS rate of 75% and an OS rate of 87%.
The authors stated that there was no significant difference in DFS or OS between the two trastuzumab-containing regimens. However, the study was not powered to detect equivalence between the two trastuzumab-containing regimens.
The rates of congestive heart failure and cardiac dysfunction were significantly higher in the group receiving AC-T plus trastuzumab than in the TCH group (P < .001).
These trial findings raise the question of whether anthracyclines are needed for the adjuvant treatment of HER2-overexpressing breast cancer. The group receiving AC-trastuzumab showed a small but not statistically significant benefit over TCH.
This trial supports the use of TCH as an alternative adjuvant regimen for women with early-stage HER2-overexpressing breast cancer, particularly in those with concerns about cardiac toxic effects.
The Finland Herceptin (FINHER) study assessed the impact of a much shorter course of trastuzumab. In this trial, 232 women younger than 67 years with node-positive or high-risk (>2 cm tumor size) node-negative HER2-overexpressing breast cancer were given nine weekly infusions of trastuzumab concurrently with docetaxel or vinorelbine followed by FEC.[134][Level of evidence A1]
Sources: 134 · Level of evidence A1
The Finland Herceptin (FINHER) study assessed the impact of a much shorter course of trastuzumab. In this trial, 232 women younger than 67 years with node-positive or high-risk (>2 cm tumor size) node-negative HER2-overexpressing breast cancer were given nine weekly infusions of trastuzumab concurrently with docetaxel or vinorelbine followed by FEC.[134][Level of evidence A1]
At a 3-year median follow-up, the risk of recurrence and/or death was significantly reduced in patients receiving trastuzumab (3-year DFS rate, 89% vs. 78%; HR, 0.41; P = .01; 95% CI, 0.21–0.83).
The difference in OS (HR, 0.41) was not statistically significant (P = .07; 95% CI, 0.16–1.08).
Several studies have compared 6 months of trastuzumab administration to 12 months.[135-137]
Several studies have compared 6 months of trastuzumab administration to 12 months.[135-137]
In an interim analysis of the PHARE trial (NCT00381901), the 2-year DFS rate was 93.8% (95% CI, 92.6%–94.9%) in the 12-month group and 91.1% (89.7%–92.4%) in the 6-month group (HR, 1.28; 95% CI, 1.05–1.56; noninferiority, P = .29).[135][Level of evidence A1]
Sources: PHARE · 135 · Level of evidence A1
Several studies have compared 6 months of trastuzumab administration to 12 months.[135-137] › In an interim analysis of the PHARE trial (NCT00381901), the 2-year DFS rate was 93.8% (95% CI, 92.6%–94.9%) in the 12-month group and 91.1% (89.7%–92.4%) in the 6-month group (HR, 1.28; 95% CI, 1.05–1.56; noninferiority, P = .29).[135][Level of evidence A1]
In the final analysis, after 704 events were observed, the adjusted HR was 1.08 (95% CI, 0.93–1.25), and the prespecified noninferiority HR of 1.15 was not excluded.
Several studies have compared 6 months of trastuzumab administration to 12 months.[135-137]
Similar results were noted in a much smaller study of 481 patients led by the Hellenic Oncology Research Group.[136][Level of evidence A1]
Sources: 136 · Level of evidence A1
In contrast, the PERSEPHONE trial (NCT00712140), which enrolled 4,088 patients who experienced 512 DFS events at the time of analysis, excluded its prespecified noninferiority margin (HR, 1.07; 90% CI, 0.93−1.24; noninferiority, P = .011).[137][Level of evidence A1]
Sources: PERSEPHONE · 137 · Level of evidence A1
The SOLD trial (NCT00593697) compared 9 weeks of trastuzumab with 1 year of trastuzumab in 2,174 women with HER2-positive breast cancer.[138]
The SOLD trial (NCT00593697) compared 9 weeks of trastuzumab with 1 year of trastuzumab in 2,174 women with HER2-positive breast cancer.[138]
Noninferiority of the 9-week treatment could not be demonstrated for DFS (HR, 1.39; 2-sided 90% CI, 1.12−1.72).[138][Level of evidence B1]
Sources: 138 · Level of evidence B1
A meta-analysis that included these trials concluded that, with respect to OS, 1 year of trastuzumab was superior to a shorter duration of therapy; however, there was no significant benefit of 1 year of therapy in patients with low-risk disease.[139][Level of evidence A1]
Sources: 139 · Level of evidence A1
Several studies have evaluated the use of SQ trastuzumab in the neoadjuvant and adjuvant settings.
Sources: Several studies
Pertuzumab
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Pertuzumab is a humanized monoclonal antibody that binds to a distinct epitope on the extracellular domain of the HER2 receptor and inhibits dimerization. Its use, in combination with trastuzumab, has been evaluated in a randomized trial in the postoperative setting.
Evidence (pertuzumab):
The Breast Intergroup (BIG) trial enrolled 4,805 women with HER2-positive cancer in a blinded comparison study. Patients received 12 months of trastuzumab plus placebo versus 12 months of trastuzumab plus pertuzumab, which were given in conjunction with standard chemotherapy and hormone therapy. The primary end point was IDFS.[125]
Sources: 125
The Breast Intergroup (BIG) trial enrolled 4,805 women with HER2-positive cancer in a blinded comparison study. Patients received 12 months of trastuzumab plus placebo versus 12 months of trastuzumab plus pertuzumab, which were given in conjunction with standard chemotherapy and hormone therapy. The primary end point was IDFS.[125]
At the time of the final analysis, the 3-year IDFS rate was 94.1% in the trastuzumab-pertuzumab group and 93.2% in the trastuzumab-placebo group (HR, 0.81; 95% CI, 0.66–1.00; P = .045).
There was no statistically significant difference in OS (a secondary end point) at the first interim analysis. The same observation was made at the third interim analysis.[140]
Sources: 140
Patients who received pertuzumab had more grade 3 diarrhea (9.8% vs. 3.7%) and were more likely to develop heart failure (0.6% vs. 0.2%) than those who received placebo.
Trastuzumab emtansine (T-DM1)
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Evidence (T-DM1 for patients who have received preoperative HER2-targeted therapy.):
In a phase III trial (KATHERINE [NCT01772472]), 1,486 women with HER2-positive disease who received a preoperative taxane-containing chemotherapy (with or without an anthracycline) along with trastuzumab with or without a second HER2 targeted agent, but who had residual disease after surgery, were randomly assigned to receive 14 cycles of adjuvant trastuzumab or T-DM1. The primary end point was IDFS.[141][Level of evidence B1]
Sources: KATHERINE · 141 · Level of evidence B1
In a phase III trial (KATHERINE [NCT01772472]), 1,486 women with HER2-positive disease who received a preoperative taxane-containing chemotherapy (with or without an anthracycline) along with trastuzumab with or without a second HER2 targeted agent, but who had residual disease after surgery, were randomly assigned to receive 14 cycles of adjuvant trastuzumab or T-DM1. The primary end point was IDFS.[141][Level of evidence B1]
At the time of a planned interim analysis, IDFS was significantly higher in the T-DM1 group than in the trastuzumab group (HRinvasive disease or death, 0.50; 95% CI, 0.39–0.64; P < .001; IDFS at 3 years, 88.3% vs. 77%).
Data on OS are immature and not significant (HR, 0.70; 95% CI, 0.47–1.05).
Patients receiving T-DM1 were more likely to discontinue treatment because of an adverse event (18% vs. 2.1%) and had a higher frequency of sensory neuropathy (18.6% vs. 6.9%), most cases of which had resolved at the time of the analysis.
On subgroup analysis, the benefit of T-DM1 was observed in all subgroups, including participants who received dual HER2-targeted therapy in the preoperative setting.
Neratinib
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Neratinib is an irreversible tyrosine kinase inhibitor of HER1, HER2, and HER4, which has been approved by the FDA for the extended adjuvant treatment of patients with early-stage HER2-positive breast cancer, to follow adjuvant trastuzumab-based therapy.
Evidence (neratinib):
In the ExteNET trial (NCT00878709), the safety and efficacy of 12 months of adjuvant neratinib was investigated in patients with early-stage HER2-positive breast cancer (n = 2,840) who had completed neoadjuvant trastuzumab up to 2 years before randomization. Patients received 240 mg of oral neratinib daily for 1 year or a placebo. The primary end point was IDFS.[142][Level of evidence A1]
Sources: ExteNET · 142 · Level of evidence A1
In the ExteNET trial (NCT00878709), the safety and efficacy of 12 months of adjuvant neratinib was investigated in patients with early-stage HER2-positive breast cancer (n = 2,840) who had completed neoadjuvant trastuzumab up to 2 years before randomization. Patients received 240 mg of oral neratinib daily for 1 year or a placebo. The primary end point was IDFS.[142][Level of evidence A1]
After a median follow-up of 5.2 years (interquartile range, 2.1–5.3), patients in the neratinib group had significantly fewer IDFS events than those in the placebo group (neratinib group, 116 events vs. placebo group, 163 events; stratified HR, 0.73; 95% CI, 0.57–0.92; P = .0083). The 5-year IDFS rate was 90.2% (95% CI, 88.3%–91.8%) in the neratinib group and 87.7% (85.7%–89.4%) in the placebo group.[143]
Sources: 143
OS data are not mature.
The most common grade 1 to 2 adverse events included diarrhea (neratinib, 55% vs. placebo, 34%), nausea (41% vs. 21%), fatigue (25% vs. 20%), vomiting (23% vs. 8%), and abdominal pain (22% vs. 10%). The FDA label recommends prophylactic loperamide during the first 56 days of therapy, and as needed thereafter to help manage diarrhea.
The most common grade 3 to 4 adverse event was diarrhea (neratinib, 40% vs. placebo, 2%). All other grade 3 to 4 adverse events occurred in 2% or less of patients.
Node-negative, small, HER2-positive breast cancer
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
There are no studies comparing different regimens in patients with node-negative, small, HER2-positive breast tumors. The following two large single-arm studies demonstrated outcomes that appear to be superior to previous results in similar patients who did not receive adjuvant therapy.
Evidence (combination regimens for node-negative, small, HER2-positive tumors):
The single-arm Adjuvant Paclitaxel and Trastuzumab (APT) trial (NCT00542451) evaluated a non–anthracycline-containing regimen, paclitaxel and trastuzumab. The trial enrolled 410 women with node-negative, small (≤3 cm), HER2-positive tumors.[144]
The single-arm Adjuvant Paclitaxel and Trastuzumab (APT) trial (NCT00542451) evaluated a non–anthracycline-containing regimen, paclitaxel and trastuzumab. The trial enrolled 410 women with node-negative, small (≤3 cm), HER2-positive tumors.[144]
After 6.5 years of follow-up, the DFS rate was 93% (95% CI, 90.4%–96.2%).[144][Level of evidence C2]
Sources: 144 · Level of evidence C2
The 10-year DFS rate was 91.3% (95% CI, 88.3%–94.4%).[145]
Sources: 145
The ATEMPT trial (NCT01853748) compared paclitaxel and trastuzumab with T-DM1 in patients with node-negative HER2-positive tumors measuring 2 cm or smaller (patients with a single micrometastatic node were eligible). The goals of the trial were to determine if T-DM1 produced fewer clinically relevant toxicities and was associated with an acceptable 3-year IDFS rate. The trial randomly assigned 383 patients to the T-DM1 arm and 114 patients to the paclitaxel and trastuzumab arm.[146]
The ATEMPT trial (NCT01853748) compared paclitaxel and trastuzumab with T-DM1 in patients with node-negative HER2-positive tumors measuring 2 cm or smaller (patients with a single micrometastatic node were eligible). The goals of the trial were to determine if T-DM1 produced fewer clinically relevant toxicities and was associated with an acceptable 3-year IDFS rate. The trial randomly assigned 383 patients to the T-DM1 arm and 114 patients to the paclitaxel and trastuzumab arm.[146]
Although the types of toxicities differed in the two treatment arms, the total number of clinically relevant toxicities was nearly identical (46% in the T-DM1 arm vs. 47% in the paclitaxel and trastuzumab arm; P = .83). However, patients who received T-DM1 reported more favorable outcomes during treatment.
The 3-year IDFS rate for patients who received T-DM1 was 97.8% (95% CI, 96.3%–99.3%), which exceeded the protocol-specified rate of 95% to reject the null hypothesis (P = .0001).[146][Level of evidence C1] Results were similar at 5 years.[147]
Sources: 146 · Level of evidence C1 · 147
Toxicity of Systemic Therapy
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Capecitabine and Fluorouracil Dosing
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
The DPYD gene encodes an enzyme that catabolizes pyrimidines and fluoropyrimidines, like capecitabine and fluorouracil. An estimated 1% to 2% of the population has germline pathogenic variants in DPYD, which lead to reduced DPD protein function and an accumulation of pyrimidines and fluoropyrimidines in the body.[1,2] Patients with the DPYD*2A variant who receive fluoropyrimidines may experience severe, life-threatening toxicities that are sometimes fatal. Many other DPYD variants have been identified, with a range of clinical effects.[1-3] Fluoropyrimidine avoidance or a dose reduction of 50% may be recommended based on the patient's DPYD genotype and number of functioning DPYD alleles.[4-6] DPYD genetic testing costs less than $200, but insurance coverage varies due to a lack of national guidelines.[7] In addition, testing may delay therapy by 2 weeks, which would not be advisable in urgent situations. This controversial issue requires further evaluation.[8]
Toxicity of Adjuvant Chemotherapy
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
The acute toxicities of the drugs used for adjuvant chemotherapy are the same as those observed when these drugs are used in other treatment settings. However, because many patients with early breast cancer have prolonged survival, long-term adverse effects are particularly important in this setting. The following two toxicities are of special concern:
Cardiotoxicity from anthracyclines.
Marrow neoplasia. A study of 20,063 patients treated in National Comprehensive Cancer Network centers found an incidence of marrow neoplasia of 0.46 per 1,000 person-years in women treated with anthracycline- and/or cyclophosphamide-containing chemotherapy. This rate was significantly higher than the rate observed in women who were treated with surgery alone (hazard ratio, 6.8; 95% confidence interval [CI], 1.3–36.1).[9]
Sources: 9
Cardiac Toxic Effects With Adjuvant Trastuzumab
Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 25, 2025. Captured 2026-09-09.
Cardiac events associated with adjuvant trastuzumab have been reported in multiple studies. Key study results include the following:
In the HERA (BIG-01-01) trial, severe congestive heart failure (CHF) (New York Heart Association class III–IV) occurred in 0.6% of patients treated with trastuzumab.[10] Symptomatic CHF occurred in 1.7% of patients in the trastuzumab arm and 0.06% of patients in the observation arm.
In the NSABP B-31 trial (NCT00004067), 31 of 850 patients in the trastuzumab arm had confirmed symptomatic cardiac events, compared with 5 of 814 patients in the control arm.[11] The 3-year cumulative incidence of cardiac events for trastuzumab-treated patients was 4.1%, compared with 0.8% of patients in the control arm (95% CI, 1.7%–4.9%).
Sources: NSABP B-31 · 11
In the NCCTG-N9831 trial, 39 cardiac events were reported in the three arms over a 3-year period. The 3-year cumulative incidence of cardiac events was 0.35% in arm A (no trastuzumab), 3.5% in arm B (trastuzumab after paclitaxel), and 2.5% in arm C, (trastuzumab concomitant with paclitaxel).
Sources: NCCTG-N9831
In the AVENTIS-TAX-GMA-302 (BCIRG 006) trial (NCT00021255), clinically symptomatic cardiac events were detected in 0.38% of patients in the doxorubicin and cyclophosphamide (AC)/docetaxel (AC-D) arm, 1.87% of patients in the AC/docetaxel/trastuzumab (AC-DH) arm, and 0.37% of patients in the docetaxel/carboplatin/trastuzumab (DCbH) arm.[12] There was also a statistically significant higher incidence of asymptomatic and persistent decrease in left ventricular ejection fraction (LVEF) in the AC-DH arm than with either the AC-D or DCbH arms.
Sources: AVENTIS-TAX-GMA-302 · 12
In the FINHER trial, none of the patients who received trastuzumab experienced clinically significant cardiac events. LVEF was preserved in all of the women receiving trastuzumab, but the number of patients receiving adjuvant trastuzumab was very low.[13]
Sources: 13
Triangle